



**Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001094
Article Type:	Research
Date Submitted by the Author:	01-Mar-2012
Complete List of Authors:	Ford, Emily; University of Queensland, School of Population Health Adams, Jon; University of Technology Sydney, Faculty of Nursing, Midwifery and Health Graves, Nicholas; QUT, IHBI
<b>Primary Subject Heading</b>:	Health economics
Secondary Subject Heading:	Complementary medicine, Cardiovascular medicine
Keywords:	HEALTH ECONOMICS, Heart failure < CARDIOLOGY, COMPLEMENTARY MEDICINE

SCHOLARONE™  
Manuscripts

Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia

Emily Ford  
School of Population Health  
University of Queensland  
Brisbane, Australia  
Postal address: PO Box 9122  
Wynnum Plaza Queensland 4178  
[emily.ford1@uqconnect.edu.au](mailto:emily.ford1@uqconnect.edu.au)  
Ph +61 (0)7 3901 1429

Professor Jon Adams  
Professor of Public Health  
Faculty of Nursing, Midwifery and Health  
University of Technology  
Sydney, Australia  
and  
Honorary Professor of Sociology  
School of Social Science  
University of Queensland  
Brisbane  
Australia  
[Jon.adams@uts.edu.au](mailto:Jon.adams@uts.edu.au)

Professor Nicholas Graves  
Professor of Health Economics  
School of Public Health and Institute for Health & Biomedical Innovation  
Queensland University of Technology  
Brisbane, Australia  
[n.graves@qut.edu.au](mailto:n.graves@qut.edu.au)

Keywords: complementary therapies, heart failure, cost-benefit analysis, crataegus extract

Word count: 3387

## ABSTRACT

### Objective

An economic model was developed to evaluate the cost-effectiveness of hawthorn extract as an adjunctive treatment for heart failure in Australia.

### Methods

A Markov model of chronic heart failure was developed using the New York Heart Association (NYHA) classification system. Classes I to IV make up the four health states. Patients may remain in the same NYHA class over time, experience an improvement of symptoms and an improvement in NYHA class, or a deterioration and worsening of NYHA class. Each NYHA class has its own decision tree. Within the decision tree some patients have been admitted to hospital and some have not, some will then die, and some will survive. Model inputs were derived from the published medical literature, and the output was Quality Adjusted Life Years (QALYs). Probabilistic Sensitivity Analysis was conducted. The Expected Value of Perfect Information (EVPI) and the Expected Value of Partial Perfect Information (EVPPI) were conducted to establish the value of further research and the ideal target for such research.

### Results

The new treatment increased costs by \$1866.78 and resulted in a gain of 0.02 QALYs. The incremental cost-effectiveness ratio was \$85,160.33 per QALY. The CEAC indicated at a threshold of \$40,000 the new treatment had a 0.29 probability of being cost-effective. The average incremental NMB was -\$1791.64, the average NMB for the standard treatment was \$92,067.49, and for the new treatment \$90,275.84. Additional research is potentially cost-effective if research is not proposed to cost more than \$325 million. Utilities is the most important target parameter group for further research.

### Conclusions

Hawthorn extract is not currently considered to be cost-effective in as an adjunctive treatment for heart failure in Australia. Further research in the area of utilities is warranted.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**INTRODUCTION**

Heart failure is a major public health concern for all Western countries <sup>1</sup>. In the United States and Europe it is the most common principal diagnosis for adults admitted to hospital aged 65 years and over. In the United States around 2% of the population have heart failure (approximately 5 million people), and each year there are 500, 000 new cases diagnosed <sup>2</sup>. The estimated prevalence in Sweden is 1.5-2%, approximately 135, 000 to 180, 000 people <sup>3</sup>.

Australian data regarding the public health significance and epidemiology of heart failure is currently limited. Estimates rely on information from large-scale population studies conducted in the United States and Europe <sup>1</sup>. It is estimated there are approximately 300,000 Australians living with chronic heart failure, and approximately 30,000 new cases diagnosed each year, with incidence rates and prevalence rising significantly with age <sup>4 5</sup>. In Australia, chronic cardiovascular diseases are associated with health care costs of over five billion dollars, and estimates put the cost of heart failure at around one billion dollars <sup>6</sup>. The mortality, morbidity and health care costs of heart failure are therefore significant <sup>4</sup>.

Heart failure is a syndrome with a range of signs and symptoms, diagnosis is based on such signs and symptoms, including dyspnoea and fatigue, and appropriate investigations, such as echocardiogram, which confirm the presence or absence of heart failure and help determine its aetiology <sup>1</sup>.

Current treatment aims to relieve and stabilise symptoms and prolong survival by stopping, stabilizing or reversing the progression of heart failure <sup>7</sup>. There are a variety of strategies used in Australia, including non-pharmacological management, pharmacological management, lifestyle changes, and the use of supportive devices, surgery, and palliative care <sup>6 8</sup>. The pharmacological approach depends on the type of heart failure and extent of the symptoms.

Despite the availability of strategies to treat and manage the chronic disease, the disability and suffering associated with heart failure is devastating <sup>7</sup>. Given this, and the large economic burden, it is reasonable to examine options not currently

considered standard therapy. Research examining the use of complementary and alternative medicine, particularly the use of hawthorn extract is showing promising results.

Hawthorn extract is a popular herbal medicine used worldwide, particularly for its cardiovascular properties<sup>9</sup>. Hawthorn extract has positive inotropic, anti-inflammatory and anti-oxidative properties; causes peripheral and coronary vasodilation; and protects against ischaemia induced arrhythmias<sup>9</sup>. A recent systematic review concluded hawthorn extract can provide significant benefits to heart failure patients as an adjunct to conventional treatment and a recent cost-effectiveness study conducted in Germany concluded hawthorn is a cost-effective treatment option especially in the early stages of heart failure<sup>10-12</sup>.

Economic evaluation is a structured method for examining the costs and consequences involved with alternative methods of treatments and/or programs, in order to inform which is the best alternative from a particular viewpoint<sup>13</sup>. The goal is to improve the use of health care resources and improve patient care<sup>14</sup>. When conducted rigorously, such formal analysis allows recommendation to be made with transparency regarding the methods, data sources and assumptions<sup>13</sup>. This further allows the process to be replicated, reviewed and even challenged.

Models allow complex situations to be organised into a single coherent form that can be used to make decisions based on comprehensive consideration of the alternative interventions by capturing the essential relationships between the factors included in the model and outcomes<sup>15 16</sup>. Markov models define diseases using clinically relevant and economically important health states, between which patients move based on the natural history of the disease, and to which cost and effectiveness outcomes are ascribed<sup>16</sup>.

The aim of this study was the construction and application of an economic decision model to evaluate hawthorn treatment as an adjunct to recommended pharmacological treatment versus recommended pharmacological management for chronic heart failure in Australia. The analysis has been conducted using a health sector perspective.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**METHODS**

**Model Description**

A four state Markov model of chronic heart failure was developed based on the New York Heart Association (NYHA) classification system using Microsoft Excel® (see Figure 1). Classes I to IV make up four discrete health states included in the model (See Table 1 for a description of the NYHA classes). A decision tree completes the model. Each NYHA class has its own decision tree. Within the decision tree patients could be hospitalised for worsening heart failure. Patients also either survived or died.

**Progression through the model**

A simulated cohort of 1000 patients aged 60 entered the model with NYHA class II heart failure and progressed through the model. Patients progress through the model in one month cycles for a duration of 5 years. After one month, patients either remained in NYHA class II or improved to NYHA class I or deteriorated. In turn, for each class of heart failure patients were either hospitalised or not hospitalised for worsening heart failure. Patients who were hospitalised or not hospitalised either survived or died. Death was a possibility from any class of heart failure. The patients accrued costs and benefits of treatment in each of the states for each cycle.

Per patient costs were required for each NYHA class. Costs were assumed to be the same for standard treatment and standard treatment with hawthorn extract, except for the additional cost of hawthorn extract. Patient health was considered as a single index utility on a zero to one scale, where 0 represents death and 1 represents perfect health. This allows the calculation of Quality Adjusted Life Years (QALYs) when combined with the mortality data and the calculation of cost per QALY ratios.

Two cohorts were modeled, one receiving standard pharmacological treatment and the other receiving standard pharmacological treatment with hawthorn extract as an adjunct. The two cohorts will progress through the model in slightly different ways and as such there will be a difference in the accumulation of costs and QALYS. It is

the differences in costs and QALYs that will determine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment.

A discount rate of 3% per year was applied to the costs and benefits. This rate is a standard choice in the literature.

**Table 1. NYHA grading of symptoms in chronic heart failure.**

NYHA Class	Description
Class I	No symptoms and limitations in ordinary physical activity.
Class II	Slight limitation of physical activity. Ordinary physical activity results in mild symptoms such as fatigue, shortness of breath, and angina.
Class III	Marked limitation of physical activity. Less than ordinary physical activity leads to symptoms.
Class IV	Severely limited. Experiences symptoms even at rest.

## Model Construction

### Disease Progression

Transition probabilities for movement between NYHA classes of heart failure were estimated from the published literature detailing the large scale international Study of the Effects of Nebivolol Intervention on Outcomes and Re-hospitalisation in Seniors with Heart Failure (SENIORS) and personal correspondence with authors<sup>17 18</sup>. A thorough literature search was conducted to identify disease progression data for each NYHA class. The search yielded a limited number of studies, of which only one was considered suitable for inclusion.

Disease progression between the Markov states was assumed to be the same for standard treatment and for standard treatment with hawthorn extract, as we were unable to identify any data to indicate that hawthorn extract altered progression through the classes of heart failure. We have incorporated a difference in mortality and a difference in the hospitalisation rate between the standard treatment and the standard treatment with hawthorn extract as an adjunct, which in turn will impact on the cost and QALY outcomes.

### Data Sources



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Mortality

Baseline mortality was derived from Australian Bureau of Statistics general population mortality data.

The mortality rate for cardiovascular causes was derived from the published literature detailing one year mortality among unselected patients with NYHA class II-IV heart failure in Switzerland <sup>19</sup>. The mortality rate increased with progression from NYHA class I to NYHA class IV, and varied depending on whether the patient was hospitalised or not. A thorough search of the literature was made to identify data for each NYHA class individually, nothing was identified and the above study was the closest to ideal. Hospitalisation was considered a major factor in cost estimation, so data broken down by hospitalisation status was considered to represent the population of heart failure patients well. Also, unselected patients were considered to represent the patient cohort more accurately than studies that focused on hospitalised patients only. As data for NYHA class I was not included, an assumption was made that mortality for NYHA class I was the same as the general population mortality.

Health Status

Estimates of health status were derived from the same source as the transition probabilities <sup>17 20</sup>. Data concerning utilities for heart failure is extremely limited, a study was identified that had specifically had developed utilities for heart failure in terms of both hospitalisation and NYHA class. However, we were unable to obtain the required data despite personal correspondence with the authors. The estimated health status used was considered the next best data source.

Health status was assumed to be the same for standard treatment and standard treatment with hawthorn extract. Hospitalisation was assumed to result in a health state lower than non-hospitalisation and a -0.1 disutility was applied to hospitalisation to reflect this.

Effect of Hawthorn

The relative risk of mortality and relative risk of hospitalisation with hawthorn extract was derived from the Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE) trial, a large scale, international, randomised, placebo-controlled, double-blind study designed to investigate the influence of hawthorn extract on mortality of patients with congestive heart failure NYHA class II



and III with at least moderately impaired left ventricular function<sup>21</sup>. To date there have only been two studies to examine the effect of hawthorn extract on heart failure progression in terms of mortality and hospitalisation. Most studies have focused on symptoms and exercise capability. SPICE enrolled nearly 3000 patients, and the Hawthorn Extract Randomised Blinded Chronic Heart Failure (HERB CHF) trial enrolled 120 patients<sup>22 23</sup>. Meta-analysis was not considered appropriate, therefore the data from SPICE was incorporated into the model.

### Costs

No Australian data was available to estimate the hospitalisation rate and number of hospitalisations, this information was derived from a United States study<sup>24</sup>.

The estimated length of stay in hospital data was obtained from Victorian Department of Health for 2010-2011, it was unavailable for each NYHA class, so it was assumed to be the same for all classes<sup>25</sup>.

The cost of a hospital admission per day was derived from the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary<sup>26</sup>.

Outpatient costs included General Practitioner (GP) visits, pathology, echocardiograms, and specialist visits. Estimates of the number of GP and specialist visits came from a combination of Australian sources and overseas studies due to the difficulty in finding complete Australian estimates. The costs came directly from the Medicare Benefits Schedule and the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary<sup>26 27</sup>.

The information for which medications are taken for each NYHA class have been taken from the National Heart Foundation guidelines for the treatment of chronic heart failure in Australia<sup>5</sup>. Information for the optimal dosages prescribed has been taken from the Australian Therapeutic Guidelines. Individual drug pricing was obtained from the most recently available online version of the Medicare Benefits Schedule. The initial version of the model has incorporated the assumption that medications are taken in 100% of patients and that dosing is optimal. The model however can be altered to consider different scenarios of medication prescription and consumption.

The dosage was assumed to be 900mg daily, consistent with the dosage used in the two most recent trials of hawthorn extract, the SPICE trial and the HERB-CHF trial<sup>21</sup>

<sup>23 28</sup>. An online search was conducted for standardised monopreparations of hawthorn leaf with flower available for purchase.

The model parameters have been listed in Table 2.

**Table 2. Parameters used in the Decision Model**

Parameter Description	Baseline Estimate	Variation/ SE (SD)	Distribution	Reference
<b>Transition Probabilities</b>		n/a	Dirichlet (Refer to Appendix 1 for method)	<sup>17</sup>
Stable NYHA class I	0.977			
Deteriorate NYHA class I to II	0.019			
Deteriorate NYHA class I to III	0.004			
Stable NYHA class II	0.981			
Improve NYHA class II to I	0.008			
Deteriorate NYHA class II to III	0.010			
Deteriorate NYHA class II to IV	0.001			
Stable NYHA class III	0.960			
Improve NYHA class III to II	0.034			
Deteriorate NYHA class III to IV	0.006			
Stable NYHA class IV	0.945			
Improve NYHA class IV to III	0.055			
<b>Hospitalisation</b>		n/a	n/a	<sup>24</sup>
probability for hospitalisation Class I	0.01518800			
probability no hospitalisation Class I	0.98481200			
probability for hospitalisation Class II	0.02397800			
probability no hospitalisation Class II	0.97602200			
probability for hospitalisation Class III	0.02397800			
probability no hospitalisation	0.97602200			

Class III				
probability for hospitalisation Class IV	0.15397000			
probability no hospitalisation Class IV	0.84603000			
<b>Length of stay in hospital estimate</b>	4.9 days	Alpha 0.1 Beta 316.81	Gamma	<sup>25</sup>
<b>Relative Risk of Hospitalisation with Hawthorn Extract</b>	1.03651200	0.080800494	Lognormal	<sup>28</sup>
<b>Costs</b>		n/a	n/a	<sup>26 27 29</sup>
Cost of hospitalisation NYHA class I	\$2,957.08			
Cost of hospitalisation NYHA class II	\$4,435.63			
Cost of hospitalisation NYHA class III	\$4,435.63			
Cost of hospitalisation NYHA class IV	\$5,914.17			
Total cost of NYHA class I with hospitalisation	\$3,141.60			
Total cost of NYHA class II with hospitalisation	\$4,639.95			
Total cost of NYHA class III with hospitalisation	\$4,684.53			
Total cost of NYHA class IV with hospitalisation	\$6,176.17			
Cost of NYHA class I no hospitalisation	\$130.30			
Cost of NYHA class II no hospitalisation	\$150.11			
Cost of NYHA class III no hospitalisation	\$194.69			
Cost of NYHA class IV no hospitalisation	\$207.79			
<b>Mortality</b>				
<b>Standardised Death Rate</b>	6.0 per 1000	n/a	n/a	<sup>30</sup>
<b>Excess Mortality</b>			Beta	<sup>19</sup>
probability of excess mortality given hospitalisation class II	0.01087776	Alpha 0.35916667	Beta 2.55750000	

probability of excess mortality given no hospitalisation class II	0.002620782	Alpha 0.43166667	Beta 13.485000	
probability of excess mortality given hospitalisation class III	0.01791369	Alpha 0.79666667	Beta 3.28666667	
probability of excess mortality given no hospitalisation class III	0.00674466	Alpha 0.72833333	Beta 8.60500000	
probability of excess mortality given hospitalisation class IV	0.05333974	Alpha 0.96416667	Beta 1.03583333	
probability of excess mortality given no hospitalisation class IV	0.00719464	Alpha 0.16583333	Beta 1.83416667	
<b>Relative Risk of Mortality with Hawthorn Extract</b>	0.90336300	0.09507420	Lognormal	<sup>28</sup>
<b>Utility</b>			Beta	<sup>17</sup>
Utility of NYHA class I no hospitalisation	0.815	Alpha 395.88	Beta 89.86	
Utility of NYHA class II no hospitalisation	0.72	Alpha 661.95	Beta 257.42	
Utility of NYHA class III no hospitalisation	0.59	Alpha 359.8075	Beta 250.0357	
Utility of NYHA class IV no hospitalisation	0.508	Alpha 51.77	Beta 50.1394	

Probabilistic Sensitivity Analysis

Uncertainty is addressed in the model using probabilistic sensitivity analysis. Statistical distributions were assigned to key model parameters to examine second-order uncertainty in the estimation of the parameter. Uncertainty was propagated through the model using Monte Carlo simulation, drawing parameter values at random 1000 times from the particular distributions. This generates a joint density of cost and QALY outcomes that summaries uncertainties in all model parameters.

Net Monetary Benefit

The incremental net monetary benefit was calculated. The difference between the average net benefit of the standard treatment and the average net benefit of the standard treatment with hawthorn as an adjunct is equal to the incremental net benefit. The net benefit for each treatment is the increase in effectiveness multiplied by the amount the decision maker is willing to pay per QALY (\$40,000), less the increase in cost.

### **The Expected Value of Perfect Information/ Expected Value of Partial Perfect Information (EVPI/ EVPPI)**

The results of the modeling will indicate whether, based on the currently available information, the new treatment should be recommended. This decision is always associated with a level of uncertainty, which raises the question of whether it is appropriate to conduct further research to better examine the potential value of the new treatment, and whether we can identify where this research needs to be directed. EVPI and EVPPI analysis have been used to address these questions.

EVPI analysis is a combination of the cost of making the wrong decision in terms of forgone health benefit and wasted resources, and the probability of making a wrong decision. This equates to the expected cost of uncertainty. With all uncertainty removed there would be economic savings from making the best decision and EVPI is a monetary value of these savings. EVPI provides an upper bound for spending on further research that reduces uncertainty in the decision. EVPPI follows the same principles, but examines individual parameters<sup>31</sup>.

For the model it has been assumed the life of technology is 10 years and the number of eligible patients per annum has been estimated at 30, 000. This estimate is derived from the estimate of 30, 000 new cases of chronic heart failure per annum.

## **RESULTS**

For the standard treatment and standard treatment with hawthorn extract as an adjunct the total cost per patient was \$4,887.82 and \$6754.59 QALYs were 2.40 and 2.42 respectively. This was an incremental cost of \$1866.78 and 0.02 QALYs, and the incremental cost-effectiveness ratio was \$85,160.33 per QALY. A Cost-

Effectiveness Plane shows the joint density of cost and QALY outcomes from the Monte Carlo simulations (See Appendix 2). The variation in the model parameters can be seen in a series of histograms for each of the probabilistic parameters (See Appendix 3).

**Cost-Effectiveness Acceptability Curve (CEAC)**

Figure 2 shows the uncertainty around this estimate as a cost-effectiveness acceptability curve (CEAC). At a willingness to pay threshold of \$40,000, the new treatment has a 0.29 probability of being cost-effective. The probability of being cost effective rises as the willingness to pay threshold rises, for a threshold between \$500,000 and \$1,000,000 the probability is 0.48.

**Net Monetary Benefit (NMB)**

For a threshold of \$40,000, the average incremental NMB is -\$1791.64, the average NMB for the standard treatment is \$92,067.49, and for the new treatment \$90,275.84. The new intervention has a negative incremental net benefit, and would not offer good value for money for a decision maker.

**Expected Value of Perfect Information (EVPI)**

The population EVPI has been plotted in Figure 3 for a cost-effectiveness threshold between \$0 and \$200, 000 per QALY. The threshold was continued in the analysis up to a threshold of \$500,000 per QALY, however this did not alter the slope of the curve, so the results up to \$200, 000 have been shown.

If the population EVPI represented in Figure 3 exceeds the expected costs of additional research, then it is potentially cost-effective to conduct further research.

At a threshold of \$40,000 additional research is potentially cost-effective if research is not proposed to cost more than \$325 million.

If we proposed additional research would cost \$100 million, it can be seen from Figure 3 that this research would be potentially cost-effective at a threshold of just under \$16,000. Even at a threshold of \$0 per QALY research would potentially be cost-effective as long as the cost of research did not exceed \$15 million.

The EVPI has indicated further research is potentially cost-effective. The Expected Value of Partial Perfect Information (EVPPPI) was examined to establish where further research would be of most benefit.

### **The Expected Value of Partial Perfect Information (EVPPPI)**

The EVPPPI was examined for six parameters/ groups of parameters, Transitions, Average Length of stay, Excess Mortality (cardiovascular mortality), Relative Risk of Hawthorn, Utilities, and the Relative Risk of Hospitalisation.

The results of the EVPPPI analysis can be seen in Figure 4 (and Table 3). From both the table and figure it can be seen that all parameters and parameter groups have significant EVPPPI, but the impact varies. Utilities (\$439,471,050.98) has the highest EVPPPI, and is therefore the most important target parameter/ parameter group for further research.

**Table 3. Partial EVPI Values for Parameters/ Parameter Groups**

Parameters	Partial EVPI
Transitions	\$7,153,571.92
Average Length of stay	\$96,900,062.41
Excess Mortality	\$105,833,952.26
Relative Risk Hawthorn	\$86,323,972.20
Utilities	\$439,471,050.98
Relative Risk Hospitalisation	\$56,991,399.70

## **DISCUSSION**

In this modelling study we examined the cost-effectiveness of hawthorn extract in addition to standard treatment for heart failure in Australia. This treatment is not considered cost-effective given the current evidence. This is the first known attempt to examine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment of chronic heart failure in Australia.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

EVPI analysis indicated that further research was likely to be of benefit, and EVPPI analysis indicated that research ideally should be targeted toward Utilities. The potential costs of further research and the particular type or types that may be required are of crucial importance to the final decision. Further research to examine Utilities will likely rely on primary data from randomized controlled trials such as the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure Study (SENIORS)<sup>17 32</sup>. Alternatively such research would require the initiation of novel research with utilities as a main outcome. This is costly research and this would certainly need to be estimated before any research was undertaken.

A limitation of this study was the relatively sparse data available for the Australian context. There is scarce data on the incidence and prevalence of heart failure. Estimates rely on information from a small number of large-scale population studies conducted in the United States and Europe<sup>1</sup>. The study of mortality in Australia is complex, heart failure is considered a ‘mode of death’ not a ‘cause of death’. Studies examining mortality in terms of the underlying cause of death risk underestimating mortality with condition such as heart failure. Mortality statistics are complicated by multiple co-morbidities, which make the underlying cause of death difficult to identify. Lack of consensus about the diagnosis of heart failure also complicates recording of the cause of death, indeed complicating any examination of heart failure. It is difficult to isolate costs for heart failure. Heart failure is grouped by the Australian Institute of Health and Welfare as an ‘other cardiovascular disease’. The exact contribution of heart failure to the burden of cardiovascular disease is at best an estimate.

Another limitation was the availability of evidence of the effectiveness of hawthorn extract. There are numerous studies supporting its use, however, very few studies that examine final outcomes such as hospitalisation and mortality. Previously conducted studies focus on reported outcomes including maximal workload, exercise tolerance, pressure-heart rate product, 6-min walk test, and left-ventricular ejection fraction. There are suggestions in the literature that the use of hawthorn extract can actually decrease the use of standard pharmacological therapy and alter the progression of

heart failure, but little rigorous evidence to support this<sup>10</sup>. If such evidence was available this would change the costs and benefits of hawthorn extract, and potentially change the cost-effectiveness of hawthorn extract as an adjunct to standard pharmacological treatment.

Should further evidence become available, the model can easily be updated and the results re-examined.

## CONCLUSION

Our analysis indicates that based on currently available evidence, hawthorn extract is not cost-effective in addition to standard pharmacological treatment for chronic heart failure in Australia. EVPI and EVPPI analysis indicates that further research is warranted, particularly in the area of utilities, pending an assessment of the estimated costs of such research.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests** None.

**Contributors** EF carried out the data collection and economic analysis. EF was responsible for the original draft. All authors contributed equally to all other aspects including drafting and revising, and approved the final manuscript.

REFERENCES

1. Krum H, Stewart S. Chronic heart failure: time to recognise this major public health problem. *Med J Aust* 2006;184:147-48.

2. McLean AS, Eslick GD, Coats AJS. The epidemiology of heart failure in Australia. *Int J Cardiol* 2007;118:370-74.

3. Agvall B, Borgquist L, Foldevi M, Dahlstrom U. Cost of heart failure in Swedish primary healthcare. *Scand J Prim Health* 2005;23:227-32.

4. Australian Institute of Health and Welfare. Heart failure: what of the future? Cat. No. AUS 34. Canberra: AIHW, 2003.

5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006., 2006.

6. Krum H, Jelinek MV, Stewart S, *et al*. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia in 2006. *Med J Aust* 2006;185:549-56.

7. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? *Nat Rev Drug Discov* 2007;6:127-39.

8. Quinn B. Pharmacological treatment of heart failure. *Crit Care Nurs Q* 2007;30:299-306.

9. Furey A, Tassell M. Towards a scientific approach in the assessment of efficacy of an herbal preparation: hawthorn (*Crataegus* spp.). *Eur J Heart Fail* 2008;10:1153-57.

10. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. *Forsch Komp Klas Nat* 2004;11:36-39.
11. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomised trials. *Am J Med* 2003;114:665-74.
12. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure (Review). *Cochrane Database Syst Rev* 2009; Issue 1. Art No: CD005312. DOI: 10.1002/14651858.CD005312.pub2.
13. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. *J Health Serv Res Po* 2008; 13:23-30.
14. Kymes S. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. *Ophthal Epidemiol* 2008;15:76-83.
15. Buxton MJ, Drummond MF, Van Hout BA, *et al.* Modelling in economic evaluation: an unavoidable fact of life. *Health Econ* 1997;6:217-27.
16. Spencer M, Briggs A, Grossman R, *et al.* Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. *Pharmacoeconomics* 2005;23:619-37.
17. Yao G, Freemantle N, Flather M, *et al.* Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. *Pharmacoeconomics* 2008;26:879-89.

18. Flather M, Shibata M, Coats A, *et al.* Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-25.

19. Muntwyler J, Abetel G, Gruner C, *et al.* One-year mortality among unselected outpatients with heart failure. *Eur Heart J* 2002;23:1861-66.

20. Yao G, Freemantle N, Calvert M, *et al.* The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J* 2007;28:42-51.

21. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) - rationale, study design and study protocol. *Eur J Heart Fail* 2000;2:431-37.

22. Zick S, Gillespie B, Aaronson K. The effect of crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10:587-93.

23. Zick S, Vautaw B, Gillespie B, *et al.* Hawthorn extract randomised blinded chronic heart failure (HERB-CHF) trial. *Eur J Heart Fail* 2009;11:990-99.

24. Cowper PA, DeLong ER, Whellan DJ, *et al.* Economic effects of beta-blocker therapy in patients with heart failure. *Am J Med* 2004;116:104-11.

25. Victorian Department of Health. Victorian health services policy and funding guidelines 2010-11 technical guidelines. Melbourne: Victorian Department of Health, 2010.

26. Queensland Health. Casemix funding model 2008-2009: component prices summary. Brisbane: Queensland Government, 2008.

27. Australian Government Department of Health and Ageing. Medicare Benefits Schedule (MBS) online. Canberra: Australian Government Department of Health and Ageing, 2010.
28. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* The efficacy and safety of crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10:1255-63.
29. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. Canberra: Australian Government Department of Health and Ageing, 2010.
30. Australian Bureau of Statistics. 3302.0 - Deaths, Australia, 2008, 2008.
31. Drummond MF, Sculpher MJ, Torrance GW, *et al.* *Methods for the economic evaluation of health care programmes*. Third ed. Oxford: Oxford University Press, 2007.
32. Gohler A, Geisler BP, Manne J, *et al.* Utility estimates for decision-analytic modelling in chronic heart failure: health states based on New York heart association classes and number of rehospitalisations. *Value Health* 2009;12:185-87.




Figure 1. Markov model and decision tree showing transitions between potential health states for chronic heart failure.

451x317mm (300 x 300 DPI)






Figure 1. Cost-Effectiveness Acceptability Curve for the New Intervention  
162x90mm (300 x 300 DPI)




Figure 1. Population Expected Value of Perfect Information (EVPI) Curve  
Note. The EVPI values have been divided by 1 million to make figure easier to read.

161x91mm (300 x 300 DPI)




Figure 1. Expected Value of Perfect Information for Parameters

Note. The Partial EVPI values have been divided by 1 million to make figure easier to read.

149x91mm (300 x 300 DPI)

Appendix 1. Calculation of the Transition Probabilities for the Markov Model

transition matrix	NYHA I	NYHA II	NYHA III	NYHA IV	Check
NYHA I	0.977	0.019	0.004	0.000	1.000
NYHA II	0.008	0.981	0.010	0.001	1.000
NYHA III	0.000	0.034	0.960	0.006	1.000
NYHA IV	0.000	0.000	0.055	0.945	1.000
					0.000

Probabilistic version

1. Observed counts

	NYHA I	NYHA II	NYHA III	NYHA IV		totals
NYHA I	59.597	1.159	0.244	0		61
NYHA II	9.6	1177.2	12	1.2		1200
NYHA III	0	28.016	791.04	4.944		824
NYHA IV	0	0	2.365	40.635		43
						2128

2. Estimated probabilities

	NYHA I	NYHA II	NYHA III	NYHA IV		totals
NYHA I	0.977	0.019	0.004	0		1
NYHA II	0.008	0.981	0.010	0.001		1
NYHA III	0	0.034	0.960	0.006		1
NYHA IV	0	0	0.055	0.945		1

3. Random number table

	NYHA I	NYHA II	NYHA III	NYHA IV
NYHA I	0.24	0.44	0.87	0.66
NYHA II	0.91	0.62	0.99	0.21
NYHA III	0.72	0.91	0.27	0.46
NYHA IV	0.26	0.18	0.92	0.46


4. Cumulative gamma/normal functions

	NYHA I	NYHA II	NYHA III	NYHA IV		totals
NYHA I	53.905	0.730	0.568	0		55
NYHA II	13.845	1188.106	20.983	0.342		1223
NYHA III	0	35.377	773.741	4.390		814
NYHA IV	0	0	4.735	39.593		44

5. Random dirichlet probabilities

	NYHA I	NYHA II	NYHA III	NYHA IV		totals
NYHA I	0.976	0.013	0.010	0		1.00
NYHA II	0.011	0.971	0.017	0.000		1.00
NYHA III	0	0.043	0.951	0.005		1.00
NYHA IV	0	0	0.107	0.893		1.00

## Appendix 2. Cost-Effectiveness Plane Showing Cost and QALY Outcomes for Markov Model




Point A = ICER


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49


For peer review only

### Appendix 3. Histograms of Individual Parameters









EVEREST Statement: Checklist for health economics paper

	Study section	Additional remarks
<b>Study design</b>		
(1) The research question is stated	Introduction	
(2) The economic importance of the research question is stated	Introduction	
(3) The viewpoint(s) of the analysis are clearly stated and justified	Introduction	
(4) The rationale for choosing the alternative programmes or interventions compared is stated	Introduction	
(5) The alternatives being compared are clearly described	Introduction; Methods	
(6) The form of economic evaluation used is stated	Introduction; Methods	
(7) The choice of form of economic evaluation is justified in relation to the questions addressed	Methods; Discussion	
<b>Data collection</b>		
(8) The source(s) of effectiveness estimates used are stated	Methods	Presented in table form and in written form
(9) Details of the design and results of effectiveness study are given (if based on single study)	N/A	Data derived from multiple sources
(10) Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of effectiveness studies)	N/A	Meta-analysis was not used
(11) The primary outcome measure(s) for the economic evaluation are clearly stated	Methods	
(12) Methods to value health states and other benefits are stated	Methods	
(13) Details of the subjects from whom valuations were obtained are given	N/A	
(14) Productivity changes (if included) are reported separately	N/A	
(15) The relevance of productivity changes to the study question is discussed	N/A	
(16) Quantities of resources are reported separately from their unit costs	Methods	
(17) Methods for the estimation of quantities and unit costs are described	Methods	
(18) Currency and price data are recorded	Methods	
(19) Details of currency of price adjustments for	NA	As the study is

inflation or currency conversion are given		looking for relative cost, then inflation would be comparable between the different treatments
(20) Details of any model used are given	Methods	
(21) The choice of model used and the key parameters on which it is based are justified	Methods	
<b>Analysis and interpretation of results</b>		
(22) Time horizon of costs and benefits is stated	Methods-Model construction; Discussion	Based on current cost estimates
(23) The discount rate(s) is stated	Methods	
(24) The choice of rate(s) is justified	N/A	
(25) An explanation is given if costs or benefits are not discounted	N/A	
(26) Details of statistical tests and confidence intervals are given for stochastic data	N/A	
(27) The approach to sensitivity analysis is given	Methods	
(28) The choice of variables for sensitivity analysis is justified	Methods	
(29) The ranges over which the variables are varied are stated	Methods, Table 2	
(30) Relevant alternatives are compared	Methods	
(31) Incremental analysis is reported	Results	
(32) Major outcomes are presented in a disaggregated as well as aggregated form	Results	
(33) The answer to the study question is given	Results Discussion; Conclusion	
(34) Conclusions follow from the data reported	Discussion; Conclusion	
(35) Conclusions are accompanied by the appropriate caveats	Discussion; Conclusion	



**Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001094.R1
Article Type:	Research
Date Submitted by the Author:	29-May-2012
Complete List of Authors:	Ford, Emily; University of Queensland, School of Population Health Adams, Jon; University of Technology Sydney, Faculty of Nursing, Midwifery and Health Graves, Nicholas; QUT, IHBI
<b>Primary Subject Heading</b>:	Health economics
Secondary Subject Heading:	Complementary medicine, Cardiovascular medicine
Keywords:	HEALTH ECONOMICS, Heart failure < CARDIOLOGY, COMPLEMENTARY MEDICINE

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia

Emily Ford  
School of Population Health  
University of Queensland  
Brisbane, Australia  
Postal address: PO Box 9122  
Wynnum Plaza Queensland 4178  
[emily.ford1@uqconnect.edu.au](mailto:emily.ford1@uqconnect.edu.au)  
Ph +61 (0)7 3901 1429

Professor Jon Adams  
Professor of Public Health  
Faculty of Nursing, Midwifery and Health  
University of Technology  
Sydney, Australia  
and  
Honorary Professor of Sociology  
School of Social Science  
University of Queensland  
Brisbane  
Australia  
[Jon.adams@uts.edu.au](mailto:Jon.adams@uts.edu.au)

Professor Nicholas Graves  
Professor of Health Economics  
School of Public Health and Institute for Health & Biomedical Innovation  
Queensland University of Technology  
Brisbane, Australia  
[n.graves@qut.edu.au](mailto:n.graves@qut.edu.au)

Keywords: complementary therapies, heart failure, cost-benefit analysis, crataegus extract

Word count: 4546

## ABSTRACT

### Objective

An economic model was developed to evaluate the cost-effectiveness of hawthorn extract as an adjunctive treatment for heart failure in Australia.

### Methods

A Markov model of chronic heart failure was developed to compare the costs and outcomes of standard treatment and standard treatment with hawthorn extract using the New York Heart Association (NYHA) classification system. Health states were defined by the New York Heart Association (NYHA) classification system and death. Classes I to IV make up the four health states. For any given cycle patients could ~~may~~ remain in the same NYHA class ~~over time~~, experience ~~an improvement of symptoms and~~ an improvement or deterioration in NYHA class, be hospitalised or die ~~or a deterioration and worsening of NYHA class.~~ ~~Each NYHA class has its own decision tree. Within the decision tree some patients have been admitted to hospital and some have not, some will then die, and some will survive.~~ Model inputs were derived from the published medical literature, and the output was Quality Adjusted Life Years (QALYs). Probabilistic Sensitivity Analysis was conducted. The Expected Value of Perfect Information (EVPI) and the Expected Value of Partial Perfect Information (EVPPi) were conducted to establish the value of further research and the ideal target for such research.

### Results

Hawthorn extract ~~The new treatment~~ increased costs by \$1866.78 and resulted in a gain of 0.02 QALYs. The incremental cost-effectiveness ratio was \$85,160.33 per QALY. The CEAC indicated at a threshold of \$40,000 the new treatment had a 0.29 probability of being cost-effective. The average incremental NMB was -\$1791.64, the average NMB for the standard treatment was \$92,067.49, and for hawthorn extract ~~the new treatment~~ \$90,275.84. Additional research is potentially cost-effective if research is not proposed to cost more than \$325 million. Utilities is the most important target parameter group for further research.

### Conclusions

Hawthorn extract is not currently considered to be cost-effective in as an adjunctive treatment for heart failure in Australia. Further research in the area of utilities is warranted.



## INTRODUCTION

Heart failure is a major public health concern for all Western countries <sup>1</sup>. In the United States and Europe it is the most common principal diagnosis for adults admitted to hospital aged 65 years and over. In the United States around 2% of the population have heart failure (approximately 5 million people), and each year there are 500, 000 new cases diagnosed <sup>2</sup>. The estimated prevalence in Sweden is 1.5-2%, approximately 135, 000 to 180, 000 people <sup>3</sup>.

Australian data regarding the public health significance and epidemiology of heart failure is currently limited. Estimates rely on information from large-scale population studies conducted in the United States and Europe <sup>1</sup>. It is estimated there are approximately 300,000 Australians living with chronic heart failure, and approximately 30,000 new cases diagnosed each year, with incidence rates and prevalence rising significantly with age <sup>4,5</sup>. In Australia, chronic cardiovascular diseases are associated with health care costs of over five billion dollars, and estimates put the cost of heart failure at around one billion dollars <sup>6</sup>. The mortality, morbidity and health care costs of heart failure are therefore significant <sup>4</sup>.

Heart failure is a syndrome with a range of signs and symptoms, diagnosis is based on such signs and symptoms, including dyspnoea and fatigue, and appropriate investigations, such as echocardiogram, which confirm the presence or absence of heart failure and help determine its aetiology <sup>1</sup>.

Current treatment aims to relieve and stabilise symptoms and prolong survival by stopping, stabilizing or reversing the progression of heart failure <sup>7</sup>. There are a variety of strategies used in Australia, including non-pharmacological management, pharmacological management, lifestyle changes, and the use of supportive devices,

surgery, and palliative care<sup>68</sup>. The pharmacological approach depends on the type of heart failure and extent of the symptoms.

Despite the availability of strategies to treat and manage the chronic disease, the disability and suffering associated with heart failure is devastating<sup>7</sup>. Given this, and the large economic burden, it is reasonable to examine options not currently considered standard therapy. Research examining the use of complementary and alternative medicine, particularly the use of hawthorn extract is showing promising results.

Hawthorn extract is a popular herbal medicine used worldwide, particularly for its cardiovascular properties<sup>9</sup>. Hawthorn extract has positive inotropic, anti-inflammatory and anti-oxidative properties; causes peripheral and coronary vasodilation; and protects against ischaemia induced arrhythmias<sup>9</sup>. A recent systematic review concluded hawthorn extract can provide significant benefits to heart failure patients as an adjunct to conventional treatment and a recent cost-effectiveness study conducted in Germany concluded hawthorn is a cost-effective treatment option especially in the early stages of heart failure<sup>10-12</sup>.

Economic evaluation is a structured method for examining the costs and consequences involved with alternative methods of treatments and/or programs, in order to inform which is the best alternative from a particular viewpoint<sup>13</sup>. The goal is to improve the use of health care resources and improve patient care<sup>14</sup>. When conducted rigorously, such formal analysis allows recommendation to be made with transparency regarding the methods, data sources and assumptions<sup>13</sup>. This further allows the process to be replicated, reviewed and even challenged.

Models allow complex situations to be organised into a single coherent form that can be used to make decisions based on comprehensive consideration of the alternative interventions by capturing the essential relationships between the factors included in the model and outcomes<sup>15 16</sup>. Markov models define diseases using clinically relevant and economically important health states, between which patients move based on the natural history of the disease, and to which cost and effectiveness outcomes are ascribed<sup>16</sup>.

There are numerous examples of cost-effectiveness modeling in heart failure that examine conventional medicine. Pharmacological, behavioural and surgical interventions have all been investigated and many found to be cost-effective<sup>17 18</sup>. Pharmacological agents that have cost-effectiveness evidence include angiotensin converting enzyme inhibitors (ACEIs), digoxin, and beta-blockers such as carvedilol and nebivolol. Multidisciplinary heart failure management, in the form of a team, usually made up of a nurse co-ordinator and support from medical staff and allied health including dieticians and physiotherapy, has also shown to be cost-effective through reductions in hospitalisation and length of stay<sup>17 19</sup>. Surgical options including heart transplant, through intensive education and maximal medical therapy, have demonstrated a range of cost-effectiveness values. Cardiac resynchronisation therapy with or without an implantable cardioverter-defibrillator, has shown to be cost-effective from a healthcare perspective<sup>17 20</sup>. Most of the recent evidence involves Markov modeling. The models in any area of health vary in terms of the Markov states chosen, for example when representing the severity of heart failure, hospitalisations and NYHA classes of heart failure are both utilised. It is difficult to summarise the multitude of evidence and compare models as different model structures and methods are used, which potentially leads to different outcomes<sup>21</sup>.

The increasing number of published health economic evaluations is not yet reflected in CAM<sup>22 23 24</sup>. A systematic review examined whether CAM demonstrated cost-effectiveness through economic evaluations<sup>25</sup>. This was based on 56 economic evaluations, 39 full economic evaluations and 14 of appropriate quality for further assessment. There was good evidence for the cost-effectiveness of several therapies in comparison to usual care, acupuncture for migraine, manual therapy for neck pain, spa therapy for Parkinson's, self-administered stress management for cancer patients undergoing chemotherapy, pre- and post-operative oral nutritional supplementation for lower gastrointestinal tract surgery, biofeedback for patients with "functional" disorders (eg, irritable bowel syndrome), and guided imagery, relaxation therapy, and a potassium rich diet for cardiac patients. There were a number of therapies that were cost-effective compared to usual care, and evidence to suggest CAM could be cost effective as a complement to usual care<sup>25</sup>.

It has been several years since this review, but a literature search suggests the situation today is similar. It is possible to identify economic evaluation of CAM, however there are few full economic evaluations. An example of such an evaluation, is a study examining therapeutic massage, exercise, and lessons in the Alexander technique for treating persistent back pain<sup>26</sup>. Costs included those to the National Health Service (NHS) and to participants. Outcome measures included the Roland-Morris disability score, days in pain, and quality adjusted life years (QALYs). Results included incremental cost effectiveness ratios and cost effectiveness acceptability curves. Massage, lessons in the Alexander technique, and an exercise prescription all provided benefits to patients over a 12-month period. A series of six lessons in the Alexander technique combined with an exercise prescription was the most effective and cost effective option for the NHS<sup>26</sup>.

Some economic evaluations of CAM have incorporated decision modeling. A recent study examined the cost • effectiveness of adding acupuncture to usual care for chronic low back pain, from a societal perspective, using a Markov model<sup>27</sup>. This led to a gain of 0.13 QALYs at an incremental cost of KRW 459,637, resulting in an incremental cost per QALY gained of KRW 3,421,394, well below the recommended threshold based on the per capita gross domestic product in Korea (KRW 20,000,000). The probability of collaborative treatment being cost • effective was 72.3%. The EVPI analysis suggested further research to reduce the uncertainty around the cost • effectiveness of collaborative treatment was of reasonable value. The authors concluded acupuncture plus usual care was more cost • effective than usual care for these patients<sup>27</sup>.

The aim of this study was the construction and application of an economic decision model to evaluate hawthorn treatment as an adjunct to recommended pharmacological treatment versus recommended pharmacological management for chronic heart failure in Australia. The analysis has been conducted using a health sector perspective.

## METHODS

### Model Description

A four state Markov model of chronic heart failure was developed based on the New York Heart Association (NYHA) classification system using Microsoft Excel® (see Figure 1). Classes I to IV make up four discrete health states included in the model (See Table 1 for a description of the NYHA classes). A decision tree completes the model. Each NYHA class has its own decision tree. Within the decision tree patients could be hospitalised for worsening heart failure. Patients also either survived or died.

**Progression through the model**

A simulated cohort of 1000 patients aged 60 entered the model with NYHA class II heart failure and progressed through the model. Patients progress through the model in one month cycles for a duration of 5 years. After one month, patients either remained in NYHA class II or improved to NYHA class I or deteriorated. In turn, for each class of heart failure patients were either hospitalised or not hospitalised for worsening heart failure. Patients who were hospitalised or not hospitalised either survived or died. Death was a possibility from any class of heart failure. The patients accrued costs and benefits of treatment in each of the states for each cycle.

Per patient costs were required for each NYHA class. Costs were assumed to be the same for standard treatment and standard treatment with hawthorn extract, except for the additional cost of hawthorn extract. Patient health was considered as a single index utility on a zero to one scale, where 0 represents death and 1 represents perfect health. This allows the calculation of Quality Adjusted Life Years (QALYs) when combined with the mortality data and the calculation of cost per QALY ratios.

Two cohorts were modeled, one receiving standard pharmacological treatment and the other receiving standard pharmacological treatment with hawthorn extract as an adjunct. The two cohorts will progress through the model in slightly different ways and as such there will be a difference in the accumulation of costs and QALYS. It is the differences in costs and QALYs that will determine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment.

A discount rate of 3% per year was applied to the costs and benefits. This rate is a standard choice in the literature.

**Table 1. NYHA grading of symptoms in chronic heart failure.**

NYHA Class	Description
Class I	No symptoms and limitations in ordinary physical activity.
Class II	Slight limitation of physical activity. Ordinary physical activity results in mild symptoms such as fatigue, shortness of breath, and angina.
Class III	Marked limitation of physical activity. Less than ordinary physical activity leads to symptoms.
Class IV	Severely limited. Experiences symptoms even at rest.

### Model Construction

#### Disease Progression

Transition probabilities for movement between NYHA classes of heart failure were estimated from the published literature detailing the large scale international Study of the Effects of Nebivolol Intervention on Outcomes and Re-hospitalisation in Seniors with Heart Failure (SENIORS) and personal correspondence with authors<sup>18, 28</sup>. A thorough literature search was conducted to identify disease progression data for each NYHA class. Data was considered relevant if transition probabilities were provided for each NYHA class. The databases searched were Medline, CINAHL and the Cochrane Library. Search terms used included 'New York Heart Association', 'NYHA', 'NYHA class', 'class', 'Markov model', 'decision model', 'chronic heart failure', and 'heart failure'.

The search yielded a limited number of studies, of which only the above study was considered suitable for inclusion.

Disease progression between the Markov states was assumed to be the same for standard treatment and for standard treatment with hawthorn extract, as we were unable to identify reliable data to indicate that hawthorn extract altered progression through the classes of heart failure. Transition probabilities were fixed over time. We have incorporated a difference in mortality and a difference in the hospitalisation rate between the standard treatment and the standard treatment with hawthorn extract as an adjunct, which in turn will impact on the cost and QALY outcomes.

**Data Sources**

**Mortality**

Baseline mortality was derived from Australian Bureau of Statistics general population mortality data.

Mortality data was of interest if it was provided for each NYHA class and if it concerned the excess mortality from heart failure and/or cardiovascular causes. The databases searched were Medline, CINAHL and the Cochrane Library. Search terms used included ‘New York Heart Association’, ‘NYHA’, ‘NYHA class’, ‘class’, ‘Markov model’, ‘decision model’, ‘chronic heart failure’, ‘heart failure’, ‘mortality’.

The mortality rate for cardiovascular causes was derived from the published literature detailing one-year mortality among unselected patients with NYHA class II-IV heart failure in Switzerland <sup>29</sup>. The mortality rate increased with progression from NYHA class I to NYHA class IV, and varied depending on whether the patient was hospitalised or not. A thorough search of the literature was made to identify data for each NYHA class individually, nothing was identified and the above study was the closest to ideal. Hospitalisation was considered a major factor in cost estimation, so data broken down by hospitalisation status was considered to represent the population of heart failure patients well. Also, unselected patients were considered to represent the patient cohort more accurately than studies that focused on hospitalised patients only. As data for NYHA class I was not included, an assumption was made that mortality for NYHA class I was the same as the general population mortality.

**Health Status**

Estimates of health status were derived from the same source as the transition probabilities <sup>18 20</sup>. Data concerning utilities for heart failure is extremely limited, a study was identified that had specifically had developed utilities for heart failure in terms of both hospitalisation and NYHA class. However, we were unable to obtain the required data despite personal correspondence with the authors. The estimated health status used was considered the next best data source.

Health status was assumed to be the same for standard treatment and standard treatment with hawthorn extract. Hospitalisation was assumed to result in a health



state lower than non-hospitalisation and a -0.1 disutility was applied to hospitalisation to reflect this.

### Effect of Hawthorn

A literature search identified the existing research for the use of hawthorn extract in the treatment of heart failure. The search included electronic databases (Medline, PubMed, CAM on PubMed, AMED, Econolite, DynaMed, CINAHL, Cochrane Database of Systematic Reviews), hand searches of the literature, including hard copies of journals, and a search of the reference lists of the articles and publications found through electronic and hand searches. Personal communication with authors and experts including manufacturers and researchers in the field was also necessary to identify other sources of information and research that may not have been found using any other methods.

A wide range of search terms was used including: 'heart failure', 'chronic heart failure', 'systolic heart failure', and 'congestive heart failure', 'hawthorn', 'Crataegus', 'Crataegus oxyacantha', 'Crataegus monogyna', 'whitethorn', 'weissdorn', 'Crataegus laevigata', 'WS 1442', 'LI 132', 'complementary', 'alternative', 'medicine' and 'therapy'. There were several studies written in German, these were translated into English and then examined.

Publicly accessible trials registers were also searched. The Australian New Zealand Clinical Trials Registry (ANZCTR) was searched, no studies were identified. The World Health Organisation International Clinical Trials Registry Platform was searched, no new relevant trials were identified. The search terms used were: 'hawthorn extract', 'hawthorn', 'crataegus', 'WS1442', 'whitehorn', 'heart failure'.

There were no planned exclusion criteria at this stage for the patient population as any of the studies found have the potential to contribute valuable information to inform the model development.

The relative risk of mortality and relative risk of hospitalisation with hawthorn extract was derived from the Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE) trial, a large scale, international, randomised, placebo-controlled, double-blind study designed to investigate the influence of



hawthorn extract on mortality of patients with congestive heart failure NYHA class II and III with at least moderately impaired left ventricular function<sup>30</sup>. To date there have only been two studies to examine the effect of hawthorn extract on heart failure progression in terms of mortality and hospitalisation. Most studies have focused on symptoms and exercise capability. SPICE enrolled ~~2681~~~~nearly 3000~~ patients, and the Hawthorn Extract Randomised Blinded Chronic Heart Failure (HERB CHF) trial enrolled 120 patients<sup>31 32</sup>. Meta-analysis was not considered appropriate, therefore the data from SPICE was incorporated into the model.

Costs

No Australian data was available to estimate the hospitalisation rate and number of hospitalisations, this information was derived from a United States study<sup>33</sup>. The estimated length of stay in hospital data was obtained from Victorian Department of Health for 2010-2011, it was unavailable for each NYHA class, so it was assumed to be the same for all classes<sup>34</sup>.

The cost of a hospital admission per day was derived from the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary (\$3,775 per day)<sup>35 26</sup>.

Outpatient costs included General Practitioner (GP) visits, pathology (urea, creatinine, electrolytes), echocardiograms, and specialist visits. Estimates of the number of GP and specialist visits came from a combination of Australian sources and overseas studies due to the difficulty in finding complete Australian estimates. It was estimated that NYHA class I had 6 GP visits per year, and the remaining NYHA classes had 12 visits per year at \$34.30 per visit. Pathology was assumed to be required every 3 months at a cost of \$17.80. An Echocardiogram was assumed to be performed every two years (\$230.65). A specialist visit was assumed to occur twice per year (\$290 initial visit, \$194 repeat visit). If hospitalized, it was assumed patients had an extra 3 specialist visits and 2 GP visits per year. The costs came directly from the Medicare Benefits Schedule and the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary<sup>35 36</sup>.

The information for which medications are taken for each NYHA class have been taken from the National Heart Foundation guidelines for the treatment of chronic heart failure in Australia<sup>5</sup>. Information for the optimal dosages prescribed has been taken from the Australian Therapeutic Guidelines. Individual drug pricing was

obtained from the most recently available online version of the Medicare Benefits Schedule. The initial version of the model has incorporated the assumption that medications are taken in 100% of patients and that dosing is optimal. The model however can be altered to consider different scenarios of medication prescription and consumption.

The dosage was assumed to be 900mg daily, consistent with the dosage used in the two most recent trials of hawthorn extract, the SPICE trial and the HERB-CHF trial<sup>30</sup><sup>32 37</sup>. An online search was conducted for standardised monopreparations of hawthorn leaf with flower available for purchase. [Cardiomax® retails for A\\$25.95.](#)

[The transition parameters are listed in Table 2.](#) The model parameters have been listed in Table 3. [Appendix 1 details the calculation of transition probabilities for the model.](#)

**Table 2. Transition Parameters used in the Decision Model**

<b>Transition Matrix</b>	<b>NYHA I</b>	<b>NYHA II</b>	<b>NYHA III</b>	<b>NYHA IV</b>	<b>Distribution</b>
<b>NYHA I</b>	0.977	0.019	0.004	0.000	Dirichlet
<b>NYHA II</b>	0.008	0.981	0.010	0.001	Dirichlet
<b>NYHA III</b>	0.000	0.034	0.960	0.006	Dirichlet
<b>NYHA IV</b>	0.000	0.000	0.055	0.945	Dirichlet

**Table 3. Parameters used in the Decision Model**

<b>Probabilistic Parameters</b>				
<b>Parameter Description</b>	<b>Baseline Estimate</b>	<b>Variation/ SE (SD)</b>	<b>Distribution</b>	<b>Reference</b>
<b>Hospitalisation</b>				
Length of stay in hospital estimate	4.9 days	Alpha 0.1 Beta 316.81	Gamma	<sup>34</sup>
Relative Risk of Hospitalisation with Hawthorn Extract	1.03651200	0.080800494	Lognormal	<sup>37</sup>
<b>Mortality</b>				
Excess Mortality			Beta	<sup>29</sup>
probability of excess mortality given hospitalisation class II	0.01087776	Alpha 0.35916667	Beta 2.55750000	
probability of excess mortality	0.002620782	Alpha 0.43166667	Beta 13.485000	

given no hospitalisation class II				
probability of excess mortality given hospitalisation class III	0.01791369	Alpha 0.79666667	Beta 3.28666667	
probability of excess mortality given no hospitalisation class III	0.00674466	Alpha 0.72833333	Beta 8.60500000	
probability of excess mortality given hospitalisation class IV	0.05333974	Alpha 0.96416667	Beta 1.03583333	
probability of excess mortality given no hospitalisation class IV	0.00719464	Alpha 0.16583333	Beta 1.83416667	
<b>Relative Risk of Mortality with Hawthorn Extract</b>	0.90336300	0.09507420	Lognormal	37
<b>Utility</b>			Beta	18
Utility of NYHA class I no hospitalisation	0.815	Alpha 395.88	Beta 89.86	
Utility of NYHA class II no hospitalisation	0.72	Alpha 661.95	Beta 257.42	
Utility of NYHA class III no hospitalisation	0.59	Alpha 359.8075	Beta 250.0357	
Utility of NYHA class IV no hospitalisation	0.508	Alpha 51.77	Beta 50.1394	
<b>Fixed Parameters</b>				
<b>Parameter Description</b>	<b>NYHA class I</b>	<b>NYHA class II</b>	<b>NYHA class III</b>	<b>NYHA class IV</b>
<b>Hospitalisation</b>				33
Probability for hospitalisation	0.01518800	0.02397800	0.02397800	0.15397000
Probability no hospitalisation	0.98481200	0.97602200	0.97602200	0.84603000
<b>Costs</b>				35 36 38
Cost of hospitalisation	\$2,957.08	\$4,435.63	\$4,435.63	\$5,914.17
Total cost for each NYHA class with hospitalisation	\$3,141.60	\$4,639.95	\$4,684.53	\$6,176.17
Cost of each class with no hospitalisation	\$130.30	\$150.11	\$194.69	\$207.79
<b>Mortality</b>				39

<b>Standardised Death Rate</b>	6.0 per 1000	6.0 per 1000	6.0 per 1000	6.0 per 1000
--------------------------------	--------------	--------------	--------------	--------------

### Probabilistic Sensitivity Analysis

Uncertainty is addressed in the model using probabilistic sensitivity analysis. Statistical distributions were assigned to key model parameters to examine second-order uncertainty in the estimation of the parameter. Uncertainty was propagated through the model using Monte Carlo simulation, drawing parameter values at random 1000 times from the particular distributions. This generates a joint density of cost and QALY outcomes that summarises uncertainty in all model parameters.

### Net Monetary Benefit

The incremental net monetary benefit was calculated. The difference between the average net benefit of the standard treatment and the average net benefit of the standard treatment with hawthorn as an adjunct is equal to the incremental net benefit. The net benefit for each treatment is the increase in effectiveness multiplied by the amount the decision maker is willing to pay per QALY (\$40,000), less the increase in cost.

### The Expected Value of Perfect Information/ Expected Value of Partial Perfect Information (EVPI/ EVPPI)

The results of the modeling will indicate whether, based on the currently available information, the new treatment should be recommended. This decision is always associated with a level of uncertainty, which raises the question of whether it is appropriate to conduct further research to better examine the potential value of the new treatment, and whether we can identify where this research needs to be directed. EVPI and EVPPI analysis have been used to address these questions.

EVPI analysis is a combination of the cost of making the wrong decision in terms of forgone health benefit and wasted resources, and the probability of making a wrong decision. This equates to the expected cost of uncertainty. With all uncertainty removed there would be economic savings from making the best decision and EVPI is a monetary value of these savings. EVPI provides an upper bound for spending on

further research that reduces uncertainty in the decision. EVPPI follows the same principles, but examines individual parameters<sup>40</sup>.

For the model it has been assumed the life of technology is 10 years and the number of eligible patients per annum has been estimated at 30, 000. This estimate is derived from the estimate of 30, 000 new cases of chronic heart failure per annum.

RESULTS

For the standard treatment and standard treatment with hawthorn extract as an adjunct the total cost per patient was \$4,887.82 and \$6754.59 QALYs were 2.40 and 2.42 respectively. This was an incremental cost of \$1866.78 and 0.02 QALYs, and the incremental cost-effectiveness ratio was \$85,160.33 per QALY. A Cost-Effectiveness Plane shows the joint density of cost and QALY outcomes from the Monte Carlo simulations (See Appendix 2). The variation in the model parameters can be seen in a series of histograms for each of the probabilistic parameters (See Appendix 3).

Cost-Effectiveness Acceptability Curve (CEAC)

Figure 2 shows the uncertainty around this estimate as a cost-effectiveness acceptability curve (CEAC). At a willingness to pay threshold of \$40,000, the ~~new~~ treatment with hawthorn extract has a 0.29 probability of being cost-effective. The probability of being cost effective rises as the willingness to pay threshold rises, for a threshold between \$500,000 and \$1,000,000 the probability is 0.48.

Net Monetary Benefit (NMB)

For a threshold of \$40,000, the average incremental NMB is -\$1791.64, the average NMB for the standard treatment is \$92,067.49, and for the standard treatment with hawthorn as an adjunct~~new treatment~~ \$90,275.84. The treatment with hawthorn extract~~new intervention~~ has a negative incremental net benefit, and would not offer good value for money for a decision maker.

Expected Value of Perfect Information (EVPI)

The population EVPI has been plotted in Figure 3 for a cost-effectiveness threshold between \$0 and \$200, 000 per QALY. The threshold was continued in the analysis up to a threshold of \$500,000 per QALY, however this did not alter the slope of the curve, so the results up to \$200, 000 have been shown.

If the population EVPI represented in Figure 3 exceeds the expected costs of additional research, then it is potentially cost-effective to conduct further research.

At a threshold of \$40,000 additional research is potentially cost-effective if research is not proposed to cost more than \$325 million.

If we proposed additional research would cost \$100 million, it can be seen from Figure 3 that this research would be potentially cost-effective at a threshold of just under \$16,000. Even at a threshold of \$0 per QALY research would potentially be cost-effective as long as the cost of research did not exceed \$15 million.

The EVPI has indicated further research is potentially cost-effective. The Expected Value of Partial Perfect Information (EVPPI) was examined to establish where further research would be of most benefit.

#### **The Expected Value of Partial Perfect Information (EVPPI)**

The EVPPI was examined for six parameters/ groups of parameters, Transitions, Average Length of stay, Excess Mortality (cardiovascular mortality), Relative Risk of Hawthorn, Utilities, and the Relative Risk of Hospitalisation.

The results of the EVPPI analysis can be seen in Figure 4 (and Table 4). From both the table and figure it can be seen that all parameters and parameter groups have significant EVPPI, but the impact varies. Utilities (\$439,471,050.98) has the highest EVPPI, and is therefore the most important target parameter/ parameter group for further research.

**Table 4. Partial EVPI Values for Parameters/ Parameter Groups**

Parameters	Partial EVPI
------------	--------------

Transitions	\$7,153,571.92
Average Length of stay	\$96,900,062.41
Excess Mortality	\$105,833,952.26
Relative Risk Hawthorn	\$86,323,972.20
Utilities	\$439,471,050.98
Relative Risk Hospitalisation	\$56,991,399.70

DISCUSSION

In this modelling study we examined the cost-effectiveness of hawthorn extract in addition to standard treatment for heart failure in Australia. This treatment is not considered cost-effective given the current evidence. This is the first known attempt to examine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment of chronic heart failure in Australia. Economic evaluation has been conducted examining hawthorn extract and standard heart failure treatment in Germany and this research indicates hawthorn extract was cost-effective in the study context, however, these studies were not considered rigorous enough for the data to be used in this study<sup>10 41</sup>.

EVPI analysis indicated that further research was likely to be of benefit, and EVPPI analysis indicated that research ideally should be targeted toward Utilities. The potential costs of further research and the particular type or types that may be required are of crucial importance to the final decision. Further research to examine Utilities will likely rely on primary data from randomized controlled trials such as the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure Study (SENIORS)<sup>18 42</sup>. Alternatively such research would require the initiation of novel research with utilities as a main outcome. This is costly research and this would certainly need to be estimated before any research was undertaken.

A limitation of this study was the relatively sparse data available for the Australian context. There is scarce data on the incidence and prevalence of heart failure.



Estimates rely on information from a small number of large-scale population studies conducted in the United States and Europe<sup>1</sup>. The study of mortality in Australia is complex, heart failure is considered a 'mode of death' not a 'cause of death'. Studies examining mortality in terms of the underlying cause of death risk underestimating mortality with condition such as heart failure. Mortality statistics are complicated by multiple co-morbidities, which make the underlying cause of death difficult to identify. Lack of consensus about the diagnosis of heart failure also complicates recording of the cause of death, indeed complicating any examination of heart failure. It is difficult to isolate costs for heart failure. Heart failure is grouped by the Australian Institute of Health and Welfare as an 'other cardiovascular disease'. The exact contribution of heart failure to the burden of cardiovascular disease is at best an estimate.

Another limitation was the availability of evidence of the effectiveness of hawthorn extract. There are numerous studies supporting its use, however, very few studies that examine final outcomes such as hospitalisation and mortality<sup>12,30,32</sup>. Previously conducted studies focus on reported outcomes including maximal workload, exercise tolerance, pressure-heart rate product, 6-min walk test, and left-ventricular ejection fraction. There are suggestions in the literature that the use of hawthorn extract can actually decrease the use of standard pharmacological therapy and alter the progression of heart failure, but little rigorous evidence to support this<sup>10</sup>. If the use of standard pharmaceuticals was decreased, and/or disease progression was altered and patients improved their NYHA class to a greater extent or remained in the less symptomatic classes for longer such evidence was available this would decrease ~~change the~~ costs ~~and benefits of hawthorn extract~~, and potentially change the cost-effectiveness in favour of adding ~~of~~ hawthorn extract as an adjunct to standard pharmacological treatment<sub>10</sub>.

Should further evidence become available, the model can easily be updated and the results re-examined.

## CONCLUSION



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Our analysis indicates that based on currently available evidence, hawthorn extract is not cost-effective in addition to standard pharmacological treatment for chronic heart failure in Australia. EVPI and EVPPI analysis indicates that further research is warranted, particularly in the area of utilities, pending an assessment of the estimated costs of such research.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests** None.

**Contributors** EF, NG and JA were responsible for the conception and design of the research. EF carried out the data collection and economic analysis. EF was responsible for the original draft. All authors contributed equally to all other aspects including drafting and revising, and approved the final manuscript.

## REFERENCES

1. Krum H, Stewart S. Chronic heart failure: time to recognise this major public health problem. *Med J Aust* 2006;184:147-48.
2. McLean AS, Eslick GD, Coats AJS. The epidemiology of heart failure in Australia. *Int J Cardiol* 2007;118:370-74.
3. Agvall B, Borgquist L, Foldevi M, Dahlstrom U. Cost of heart failure in Swedish primary healthcare. *Scand J Prim Health* 2005;23:227-32.
4. Australian Institute of Health and Welfare. Heart failure: what of the future? Cat. No. AUS 34. Canberra: AIHW, 2003.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006., 2006.
6. Krum H, Jelinek MV, Stewart S, *et al.* Guidelines for the prevention, detection and management of people with chronic heart failure in Australia in 2006. *Med J Aust* 2006;185:549-56.
7. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? *Nat Rev Drug Discov* 2007;6:127-39.
8. Quinn B. Pharmacological treatment of heart failure. *Crit Care Nurs Q* 2007;30:299-306.
9. Furey A, Tassell M. Towards a scientific approach in the assessment of efficacy of an herbal preparation: hawthorn (*Crataegus* spp.). *Eur J Heart Fail* 2008;10:1153-57.

10. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. *Forsch Komp Klas Nat* 2004;11:36-39.

11. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomised trials. *Am J Med* 2003;114:665-74.

12. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure (Review). *Cochrane Database Syst Rev* 2009; Issue 1. Art No: CD005312. DOI: 10.1002/14651858.CD005312.pub2.

13. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. *J Health Serv Res Po* 2008; 13:23-30.

14. Kymes S. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. *Ophthal Epidemiol* 2008;15:76-83.

15. Buxton MJ, Drummond MF, Van Hout BA, *et al.* Modelling in economic evaluation: an unavoidable fact of life. *Health Econ* 1997;6:217-27.

16. Spencer M, Briggs A, Grossman R, *et al.* Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. *Pharmacoeconomics* 2005;23:619-37.

17. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure *Arch Intern Med* 1999;159:1690-700.

18. Yao G, Freemantle N, Flather M, *et al.* Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. *Pharmacoeconomics* 2008;26:879-89.

19. Miller G, Randolph S, Forkner E, *et al.* Long-term cost-effectiveness of disease management in systolic heart failure. *Med Decis Making OnlineFirst* 2009.
20. Yao G, Freemantle N, Calvert M, *et al.* The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J* 2007;28:42-51.
21. Turner D, Raftery J, Cooper K, *et al.* The CHD challenge: Comparing four cost-effectiveness models. *Value Health* 2011;14:53-60.
22. Canter P, Thompson-Coon J, Ernst E. Cost effectiveness of complementary treatments in the United Kingdom: a systematic review. *Brit Med J* 2005;331:880-81.
23. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? *Cost Eff Resour Alloc* 2008;6:9.
24. Thompson T, Feder G. Complementary therapies and the NHS: uncertain evidence of cost effectiveness should not exclude complementary medicine from reviews and guidelines. *Brit Med J* 2005;331:856-57.
25. Herman P, Craig B, Caspi O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. *BMC Complem Altern M* 2005;5:11.
26. Hollinghurst S, Sharp D, Ballard K, *et al.* Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. *Brit Med J Online First* 2008;337:a2656.
27. Kim N, Yang B, Lee T, *et al.* An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov model decision analysis. *BMC Complem Altern M* 2010;10:274.

28. Flather M, Shibata M, Coats A, *et al.* Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-25.
29. Muntwyler J, Abetel G, Gruner C, *et al.* One-year mortality among unselected outpatients with heart failure. *Eur Heart J* 2002;23:1861-66.
30. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) - rationale, study design and study protocol. *Eur J Heart Fail* 2000;2:431-37.
31. Zick S, Gillespie B, Aaronson K. The effect of crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10:587-93.
32. Zick S, Vautaw B, Gillespie B, *et al.* Hawthorn extract randomised blinded chronic heart failure (HERB-CHF) trial. *Eur J Heart Fail* 2009;11:990-99.
33. Cowper PA, DeLong ER, Whellan DJ, *et al.* Economic effects of beta-blocker therapy in patients with heart failure. *Am J Med* 2004;116:104-11.
34. Victorian Department of Health. Victorian health services policy and funding guidelines 2010-11 technical guidelines. Melbourne: Victorian Department of Health, 2010.
35. Queensland Health. Casemix funding model 2008-2009: component prices summary. Brisbane: Queensland Government, 2008.
36. Australian Government Department of Health and Ageing. Medicare Benefits Schedule (MBS) online. Canberra: Australian Government Department of Health and Ageing, 2010.

37. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* The efficacy and safety of crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10:1255-63.
38. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. Canberra: Australian Government Department of Health and Ageing, 2010.
39. Australian Bureau of Statistics. 3302.0 - Deaths, Australia, 2008, 2008.
40. Drummond MF, Sculpher MJ, Torrance GW, *et al.* *Methods for the economic evaluation of health care programmes*. Third ed. Oxford: Oxford University Press, 2007.
41. Koller M, Lorenz W, Aubke W, *et al.* Crataegus special extract WS 1442 in the treatment of early stages of CHD-associated heart failure *MMW Fortschr Med* 2006;148:42.
42. Gohler A, Geisler BP, Manne J, *et al.* Utility estimates for decision-analytic modelling in chronic heart failure: health states based on New York heart association classes and number of rehospitalisations. *Value Health* 2009;12:185-87.




Figure 1. Markov model and decision tree showing transitions between potential health states for chronic heart failure.

451x317mm (300 x 300 DPI)




Figure 1. Cost-Effectiveness Acceptability Curve for the New Intervention  
162x90mm (300 x 300 DPI)






Figure 1. Population Expected Value of Perfect Information (EVPI) Curve  
Note. The EVPI values have been divided by 1 million to make figure easier to read.

161x91mm (300 x 300 DPI)




Figure 1. Expected Value of Perfect Information for Parameters

Note. The Partial EVPI values have been divided by 1 million to make figure easier to read.

149x91mm (300 x 300 DPI)

Appendix 1. Calculation of the Transition Probabilities for the Markov Model

transition matrix	NYHA I	NYHA II	NYHA III	NYHA IV	Check
NYHA I	0.977	0.019	0.004	0.000	1.000
NYHA II	0.008	0.981	0.010	0.001	1.000
NYHA III	0.000	0.034	0.960	0.006	1.000
NYHA IV	0.000	0.000	0.055	0.945	1.000
					0.000

Probabilistic version

1. Observed counts

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	59.597	1.159	0.244	0	61
NYHA II	9.6	1177.2	12	1.2	1200
NYHA III	0	28.016	791.04	4.944	824
NYHA IV	0	0	2.365	40.635	43
					2128

2. Estimated probabilities

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	0.977	0.019	0.004	0	1
NYHA II	0.008	0.981	0.010	0.001	1
NYHA III	0	0.034	0.960	0.006	1
NYHA IV	0	0	0.055	0.945	1

3. Random number table

	NYHA I	NYHA II	NYHA III	NYHA IV
NYHA I	0.24	0.44	0.87	0.66
NYHA II	0.91	0.62	0.99	0.21
NYHA III	0.72	0.91	0.27	0.46
NYHA IV	0.26	0.18	0.92	0.46


4. Cumulative gamma/normal functions

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	53.905	0.730	0.568	0	55
NYHA II	13.845	1188.106	20.983	0.342	1223
NYHA III	0	35.377	773.741	4.390	814
NYHA IV	0	0	4.735	39.593	44

5. Random dirichlet probabilities

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	0.976	0.013	0.010	0	1.00
NYHA II	0.011	0.971	0.017	0.000	1.00
NYHA III	0	0.043	0.951	0.005	1.00
NYHA IV	0	0	0.107	0.893	1.00

## Appendix 2. Cost-Effectiveness Plane Showing Cost and QALY Outcomes for Markov Model





Point A = ICER


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

### Appendix 3. Histograms of Individual Parameters









EVEREST Statement: Checklist for health economics paper

	Study section	Additional remarks
<b>Study design</b>		
(1) The research question is stated	Introduction	
(2) The economic importance of the research question is stated	Introduction	
(3) The viewpoint(s) of the analysis are clearly stated and justified	Introduction	
(4) The rationale for choosing the alternative programmes or interventions compared is stated	Introduction	
(5) The alternatives being compared are clearly described	Introduction; Methods	
(6) The form of economic evaluation used is stated	Introduction; Methods	
(7) The choice of form of economic evaluation is justified in relation to the questions addressed	Methods; Discussion	
<b>Data collection</b>		
(8) The source(s) of effectiveness estimates used are stated	Methods	Presented in table form and in written form
(9) Details of the design and results of effectiveness study are given (if based on single study)	N/A	Data derived from multiple sources
(10) Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of effectiveness studies)	N/A	Meta-analysis was not used
(11) The primary outcome measure(s) for the economic evaluation are clearly stated	Methods	
(12) Methods to value health states and other benefits are stated	Methods	
(13) Details of the subjects from whom valuations were obtained are given	N/A	
(14) Productivity changes (if included) are reported separately	N/A	
(15) The relevance of productivity changes to the study question is discussed	N/A	
(16) Quantities of resources are reported separately from their unit costs	Methods	
(17) Methods for the estimation of quantities and unit costs are described	Methods	
(18) Currency and price data are recorded	Methods	
(19) Details of currency of price adjustments for	NA	As the study is

inflation or currency conversion are given		looking for relative cost, then inflation would be comparable between the different treatments
(20) Details of any model used are given	Methods	
(21) The choice of model used and the key parameters on which it is based are justified	Methods	
<b>Analysis and interpretation of results</b>		
(22) Time horizon of costs and benefits is stated	Methods-Model construction; Discussion	Based on current cost estimates
(23) The discount rate(s) is stated	Methods	
(24) The choice of rate(s) is justified	N/A	
(25) An explanation is given if costs or benefits are not discounted	N/A	
(26) Details of statistical tests and confidence intervals are given for stochastic data	N/A	
(27) The approach to sensitivity analysis is given	Methods	
(28) The choice of variables for sensitivity analysis is justified	Methods	
(29) The ranges over which the variables are varied are stated	Methods, Table 2	
(30) Relevant alternatives are compared	Methods	
(31) Incremental analysis is reported	Results	
(32) Major outcomes are presented in a disaggregated as well as aggregated form	Results	
(33) The answer to the study question is given	Results Discussion; Conclusion	
(34) Conclusions follow from the data reported	Discussion; Conclusion	
(35) Conclusions are accompanied by the appropriate caveats	Discussion; Conclusion	



**Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001094.R2
Article Type:	Research
Date Submitted by the Author:	13-Jul-2012
Complete List of Authors:	Ford, Emily; University of Queensland, School of Population Health Adams, Jon; University of Technology Sydney, Faculty of Nursing, Midwifery and Health Graves, Nicholas; QUT, IHBI
<b>Primary Subject Heading</b>:	Health economics
Secondary Subject Heading:	Complementary medicine, Cardiovascular medicine
Keywords:	HEALTH ECONOMICS, Heart failure < CARDIOLOGY, COMPLEMENTARY MEDICINE

SCHOLARONE™  
Manuscripts

# Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia

Emily Ford  
School of Population Health  
University of Queensland  
Brisbane, Australia  
Postal address: PO Box 9122  
Wynnum Plaza Queensland 4178  
[emily.ford1@uqconnect.edu.au](mailto:emily.ford1@uqconnect.edu.au)  
Ph +61 (0)7 3901 1429

Professor Jon Adams  
Professor of Public Health  
Faculty of Nursing, Midwifery and Health  
University of Technology  
Sydney, Australia  
and  
Honorary Professor of Sociology  
School of Social Science  
University of Queensland  
Brisbane  
Australia  
[Jon.adams@uts.edu.au](mailto:Jon.adams@uts.edu.au)

Professor Nicholas Graves  
Professor of Health Economics  
School of Public Health and Institute for Health & Biomedical Innovation  
Queensland University of Technology  
Brisbane, Australia  
[n.graves@qut.edu.au](mailto:n.graves@qut.edu.au)

Keywords: complementary therapies, heart failure, cost-benefit analysis, crataegus extract

Word count: 4546

## ABSTRACT

### Objective

An economic model was developed to evaluate the cost-effectiveness of hawthorn extract as an adjunctive treatment for heart failure in Australia.

### Methods

A Markov model of chronic heart failure was developed to compare the costs and outcomes of standard treatment and standard treatment with hawthorn extract. Health states were defined by the New York Heart Association (NYHA) classification system and death. For any given cycle patients could remain in the same NYHA class, experience an improvement or deterioration in NYHA class, be hospitalised or die. Model inputs were derived from the published medical literature, and the output was Quality Adjusted Life Years (QALYs). Probabilistic Sensitivity Analysis was conducted. The Expected Value of Perfect Information (EVPI) and the Expected Value of Partial Perfect Information (EVPPPI) were conducted to establish the value of further research and the ideal target for such research.

### Results

Hawthorn extract increased costs by \$1866.78 and resulted in a gain of 0.02 QALYs. The incremental cost-effectiveness ratio was \$85,160.33 per QALY. The CEAC indicated at a threshold of \$40,000 the new treatment had a 0.29 probability of being cost-effective. The average incremental NMB was -\$1791.64, the average NMB for the standard treatment was \$92,067.49, and for hawthorn extract \$90,275.84. Additional research is potentially cost-effective if research is not proposed to cost more than \$325 million. Utilities is the most important target parameter group for further research.

### Conclusions

Hawthorn extract is not currently considered to be cost-effective in as an adjunctive treatment for heart failure in Australia. Further research in the area of utilities is warranted.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**INTRODUCTION**

Heart failure is a major public health concern for all Western countries <sup>1</sup>. In the United States and Europe it is the most common principal diagnosis for adults admitted to hospital aged 65 years and over. In the United States around 2% of the population have heart failure (approximately 5 million people), and each year there are 500, 000 new cases diagnosed <sup>2</sup>. The estimated prevalence in Sweden is 1.5-2%, approximately 135, 000 to 180, 000 people <sup>3</sup>.

Australian data regarding the public health significance and epidemiology of heart failure is currently limited. Estimates rely on information from large-scale population studies conducted in the United States and Europe <sup>1</sup>. It is estimated there are approximately 300,000 Australians living with chronic heart failure, and approximately 30,000 new cases diagnosed each year, with incidence rates and prevalence rising significantly with age <sup>4 5</sup>. In Australia, chronic cardiovascular diseases are associated with health care costs of over five billion dollars, and estimates put the cost of heart failure at around one billion dollars <sup>6</sup>. The mortality, morbidity and health care costs of heart failure are therefore significant <sup>4</sup>.

Heart failure is a syndrome with a range of signs and symptoms, diagnosis is based on such signs and symptoms, including dyspnoea and fatigue, and appropriate investigations, such as echocardiogram, which confirm the presence or absence of heart failure and help determine its aetiology <sup>1</sup>.

Current treatment aims to relieve and stabilise symptoms and prolong survival by stopping, stabilizing or reversing the progression of heart failure <sup>7</sup>. There are a variety of strategies used in Australia, including non-pharmacological management, pharmacological management, lifestyle changes, and the use of supportive devices, surgery, and palliative care <sup>6 8</sup>. The pharmacological approach depends on the type of heart failure and extent of the symptoms.

Despite the availability of strategies to treat and manage the chronic disease, the disability and suffering associated with heart failure is devastating <sup>7</sup>. Given this, and the large economic burden, it is reasonable to examine options not currently

considered standard therapy. Research examining the use of complementary and alternative medicine, particularly the use of hawthorn extract is showing promising results.

Hawthorn extract is a popular herbal medicine used worldwide, particularly for its cardiovascular properties<sup>9</sup>. Hawthorn extract has positive inotropic, anti-inflammatory and anti-oxidative properties; causes peripheral and coronary vasodilation; and protects against ischaemia induced arrhythmias<sup>9</sup>. A recent systematic review concluded hawthorn extract can provide significant benefits to heart failure patients as an adjunct to conventional treatment and a recent cost-effectiveness study conducted in Germany concluded hawthorn is a cost-effective treatment option especially in the early stages of heart failure<sup>10-12</sup>.

Economic evaluation is a structured method for examining the costs and consequences involved with alternative methods of treatments and/or programs, in order to inform which is the best alternative from a particular viewpoint<sup>13</sup>. The goal is to improve the use of health care resources and improve patient care<sup>14</sup>. When conducted rigorously, such formal analysis allows recommendation to be made with transparency regarding the methods, data sources and assumptions<sup>13</sup>. This further allows the process to be replicated, reviewed and even challenged.

Models allow complex situations to be organised into a single coherent form that can be used to make decisions based on comprehensive consideration of the alternative interventions by capturing the essential relationships between the factors included in the model and outcomes<sup>15 16</sup>. Markov models define diseases using clinically relevant and economically important health states, between which patients move based on the natural history of the disease, and to which cost and effectiveness outcomes are ascribed<sup>16</sup>.

There are numerous examples of cost-effectiveness modeling in heart failure that examine conventional medicine. Pharmacological, behavioural and surgical interventions have all been investigated and many found to be cost-effective<sup>17 18</sup>. Pharmacological agents that have cost-effectiveness evidence include angiotensin converting enzyme inhibitors (ACEIs), digoxin, and beta-blockers such as carvedilol



and nebivolol. Multidisciplinary heart failure management, in the form of a team, usually made up of a nurse co-ordinator and support from medical staff and allied health including dieticians and physiotherapy, has also shown to be cost-effective through reductions in hospitalisation and length of stay<sup>17 19</sup>. Surgical options including heart transplant, through intensive education and maximal medical therapy, have demonstrated a range of cost-effectiveness values. Cardiac resynchronisation therapy with or without an implantable cardioverter-defibrillator, has shown to be cost-effective from a healthcare perspective<sup>17 20</sup>. Most of the recent evidence involves Markov modeling.

The increasing number of published health economic evaluations is not yet reflected in CAM<sup>21 22 23</sup>. A systematic review examined whether CAM demonstrated cost-effectiveness through economic evaluations<sup>24</sup>. There was good evidence for the cost-effectiveness of several therapies in comparison to usual care, acupuncture for migraine, manual therapy for neck pain, spa therapy for Parkinson's, self-administered stress management for cancer patients undergoing chemotherapy, pre- and post-operative oral nutritional supplementation for lower gastrointestinal tract surgery, biofeedback for patients with "functional" disorders (eg, irritable bowel syndrome), and guided imagery, relaxation therapy, and a potassium rich diet for cardiac patients<sup>24</sup>.

There remain very few full economic evaluations today. One such evaluation examined therapeutic massage, exercise, and lessons in the Alexander technique for treating persistent back pain<sup>25</sup>. Massage, lessons in the Alexander technique, and an exercise prescription all provided benefits to patients over a 12-month period. Six lessons in the Alexander technique combined with an exercise prescription was the most cost effective option for the NHS<sup>25</sup>. Some economic evaluations of CAM have incorporated decision modeling. Recently, the cost-effectiveness of adding acupuncture to usual care for chronic low back pain was examined, using a Markov model<sup>26</sup>. The result was an incremental cost per QALY gained of KRW 3,421,394, well below the threshold of KRW 20,000,000. Acupuncture plus usual care was more cost-effective than usual care for these patients. The probability of collaborative treatment being cost-effective was 72.3%. EVPI analysis suggested further research



was of reasonable value<sup>26</sup>. This highlights the need for full economic evaluations in many areas of CAM.

The aim of this study was the construction and application of an economic decision model to evaluate hawthorn treatment as an adjunct to recommended pharmacological treatment versus recommended pharmacological management for chronic heart failure in Australia. The analysis has been conducted using a health sector perspective.

## METHODS

### Model Description

A four state Markov model of chronic heart failure was developed based on the New York Heart Association (NYHA) classification system using Microsoft Excel® (see Figure 1). Classes I to IV make up four discrete health states included in the model (See Table 1 for a description of the NYHA classes). A decision tree completes the model. Each NYHA class has its own decision tree. Within the decision tree patients could be hospitalised for worsening heart failure. Patients also either survived or died.

### Progression through the model

A simulated cohort of 1000 patients aged 60 entered the model with NYHA class II heart failure and progressed through the model. Patients progress through the model in one month cycles for a duration of 5 years. After one month, patients either remained in NYHA class II or improved to NYHA class I or deteriorated. In turn, for each class of heart failure patients were either hospitalised or not hospitalised for worsening heart failure. Patients who were hospitalised or not hospitalised either survived or died. Death was a possibility from any class of heart failure. The patients accrued costs and benefits of treatment in each of the states for each cycle.

Per patient costs were required for each NYHA class. Costs were assumed to be the same for standard treatment and standard treatment with hawthorn extract, except for the additional cost of hawthorn extract. Patient health was considered as a single index utility on a zero to one scale, where 0 represents death and 1 represents

perfect health. This allows the calculation of Quality Adjusted Life Years (QALYs) when combined with the mortality data and the calculation of cost per QALY ratios.

Two cohorts were modeled, one receiving standard pharmacological treatment and the other receiving standard pharmacological treatment with hawthorn extract as an adjunct. The two cohorts will progress through the model in slightly different ways and as such there will be a difference in the accumulation of costs and QALYS. It is the differences in costs and QALYs that will determine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment.

A discount rate of 3% per year was applied to the costs and benefits. This rate is a standard choice in the literature.

**Table 1. NYHA grading of symptoms in chronic heart failure.**

NYHA Class	Description
Class I	No symptoms and limitations in ordinary physical activity.
Class II	Slight limitation of physical activity. Ordinary physical activity results in mild symptoms such as fatigue, shortness of breath, and angina.
Class III	Marked limitation of physical activity. Less than ordinary physical activity leads to symptoms.
Class IV	Severely limited. Experiences symptoms even at rest.

**Model Construction**

**Disease Progression**

Transition probabilities for movement between NYHA classes of heart failure were estimated from the published literature detailing the large scale international Study of the Effects of Nebivolol Intervention on Outcomes and Re-hospitalisation in Seniors with Heart Failure (SENIORS) and personal correspondence with authors<sup>18, 27</sup>. A thorough literature search was conducted to identify disease progression data for each NYHA class, between January 2004 and December 2009. Data was considered relevant if transition probabilities were provided for each NYHA class. The databases searched were Medline, CINAHL and the Cochrane Library. Search terms used included ‘New York Heart Association’, ‘NYHA’, ‘NYHA class’, ‘class’, ‘Markov model’, ‘chronic heart failure’, and ‘heart failure’.

The search yielded a limited number of studies (17 in Medline, 3 in CINAHL and 3 in the Cochrane library), of which only the above study was considered suitable for inclusion.

Disease progression between the Markov states was assumed to be the same for standard treatment and for standard treatment with hawthorn extract, as we were unable to identify reliable data to indicate that hawthorn extract altered progression through the classes of heart failure. Transition probabilities were fixed over time. We have incorporated a difference in mortality and a difference in the hospitalisation rate between the standard treatment and the standard treatment with hawthorn extract as an adjunct, which in turn will impact on the cost and QALY outcomes.

## Data Sources

### Mortality

Baseline mortality was derived from Australian Bureau of Statistics general population mortality data.

Mortality data was of interest if it was provided for each NYHA class and if it concerned the excess mortality from heart failure and/or cardiovascular causes. The databases searched were Medline, CINAHL and the Cochrane Library, between January 2004 and December 2009. Search terms used included 'New York Heart Association', 'NYHA', 'NYHA class', 'class', 'Markov model', 'chronic heart failure', 'heart failure', 'mortality'. 83 papers were identified in Medline, 198 in CINAHL and 411 in Cochrane.

The mortality rate for cardiovascular causes was derived from the published literature detailing one-year mortality among unselected patients with NYHA class II-IV heart failure in Switzerland<sup>28</sup>. The mortality rate increased with progression from NYHA class I to NYHA class IV, and varied depending on whether the patient was hospitalised or not. A thorough search of the literature was made to identify data for each NYHA class individually, nothing was identified and the above study was the closest to ideal. Hospitalisation was considered a major factor in cost estimation, so data broken down by hospitalisation status was considered to represent the population of heart failure patients well. Also, unselected patients were considered to represent the patient cohort more accurately than studies that focused on hospitalised patients

only. As data for NYHA class I was not included, an assumption was made that mortality for NYHA class I was the same as the general population mortality.

Health Status

Estimates of health status were derived from the same source as the transition probabilities<sup>18 20</sup>. Data concerning utilities for heart failure is extremely limited, a study was identified that had specifically had developed utilities for heart failure in terms of both hospitalisation and NYHA class. However, we were unable to obtain the required data despite personal correspondence with the authors. The estimated health status used was considered the next best data source. Health status was assumed to be the same for standard treatment and standard treatment with hawthorn extract. Hospitalisation was assumed to result in a health state lower than non-hospitalisation and a -0.1 disutility was applied to hospitalisation to reflect this.

Effect of Hawthorn

A literature search identified the existing research for the use of hawthorn extract in the treatment of heart failure, between January 2004 and January 2010. The search included electronic databases (Medline,(472 papers) AMED (129 papers), Econlit (0 papers), CINAHL (15 papers), Cochrane Database of Systematic Reviews (71 papers)), hand searches of the literature, including hard copies of journals, and a search of the reference lists of the articles and publications found through electronic and hand searches. Personal communication with authors and experts including manufacturers and researchers in the field was also necessary to identify other sources of information and research that may not have been found using any other methods.

A wide range of search terms was used including: ‘heart failure’, ‘chronic heart failure’, ‘systolic heart failure’, and ‘congestive heart failure’, ‘hawthorn’, ‘Crataegus’, ‘Crataegus oxyacantha’, ‘Crataegus monogyna’, ‘whitethorn’, ‘weissdorn’, ‘Crataegus laevigata’, ‘WS 1442’, ‘LI 132’, ‘complementary’, ‘alternative’, ‘medicine’ and ‘therapy’. There were several studies written in German, these were translated into English and then examined.

Publicly accessible trials registers were also searched, and information was current up to December 2011. The Australian New Zealand Clinical Trials Registry (ANZCTR) was searched, no studies were identified. The World Health Organisation International Clinical Trials Registry Platform was searched, no new relevant trials were identified. The search terms used were: 'hawthorn extract', 'hawthorn', 'crataegus', 'WS1442', 'whitehorn', 'heart failure'.

There were no planned exclusion criteria at this stage for the patient population as any of the studies found have the potential to contribute valuable information to inform the model development.

The relative risk of mortality and relative risk of hospitalisation with hawthorn extract was derived from the Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE) trial, a large scale, international, randomised, placebo-controlled, double-blind study designed to investigate the influence of hawthorn extract on mortality of patients with congestive heart failure NYHA class II and III with at least moderately impaired left ventricular function<sup>29</sup>. To date there have only been two studies to examine the effect of hawthorn extract on heart failure progression in terms of mortality and hospitalisation. Most studies have focused on symptoms and exercise capability. SPICE enrolled 2681 patients, and the Hawthorn Extract Randomised Blinded Chronic Heart Failure (HERB CHF) trial enrolled 120 patients<sup>30 31</sup>. Meta-analysis was not considered appropriate, therefore the data from SPICE was incorporated into the model.

### Costs

No Australian data was available to estimate the hospitalisation rate and number of hospitalisations, this information was derived from a United States study<sup>32</sup>.

The estimated length of stay in hospital data was obtained from Victorian Department of Health for 2010-2011, it was unavailable for each NYHA class, so it was assumed to be the same for all classes<sup>33</sup>.

The cost of a hospital admission per day was derived from the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary (\$3,775 per day)<sup>34</sup>.

Outpatient costs included General Practitioner (GP) visits, pathology (urea, creatinine, electrolytes), echocardiograms, and specialist visits. Estimates of the number of GP and specialist visits came from a combination of Australian sources and overseas studies due to the difficulty in finding complete Australian estimates. It was estimated that NYHA class I had 6 GP visits per year, and the remaining NYHA classes had 12 visits per year at \$34.30 per visit. Pathology was assumed to be required every 3 months at a cost of \$17.80. An Echocardiogram was assumed to be performed every two years (\$230.65). A specialist visit was assumed to occur twice per year (\$290 initial visit, \$194 repeat visit). If hospitalized, it was assumed patients had an extra 3 specialist visits and 2 GP visits per year. The costs came directly from the Medicare Benefits Schedule and the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary<sup>34 35</sup>.

The information for which medications are taken for each NYHA class have been taken from the National Heart Foundation guidelines for the treatment of chronic heart failure in Australia<sup>5</sup>. Information for the optimal dosages prescribed has been taken from the Australian Therapeutic Guidelines. Individual drug pricing was obtained from the most recently available online version of the Medicare Benefits Schedule. The initial version of the model has incorporated the assumption that medications are taken in 100% of patients and that dosing is optimal. The model however can be altered to consider different scenarios of medication prescription and consumption.

The dosage was assumed to be 900mg daily, consistent with the dosage used in the two most recent trials of hawthorn extract, the SPICE trial and the HERB-CHF trial<sup>29 31 36</sup>. An online search was conducted for standardised monopreparations of hawthorn leaf with flower available for purchase. Cardiomax® retails for A\$25.95 for 30 x 450mg tablets (this equates to a 15 day supply, the cost for one month is \$51.90).

The transition parameters are listed in Table 2. The model parameters have been listed in Table 3. Appendix 1 details the calculation of transition probabilities for the model.

**Table 2. Transition Parameters used in the Decision Model**

<b>Transition Matrix</b>	<b>NYHA I</b>	<b>NYHA II</b>	<b>NYHA III</b>	<b>NYHA IV</b>	<b>Distribution</b>
<b>NYHA I</b>	0.977	0.019	0.004	0.000	Dirichlet
<b>NYHA II</b>	0.008	0.981	0.010	0.001	Dirichlet
<b>NYHA III</b>	0.000	0.034	0.960	0.006	Dirichlet
<b>NYHA IV</b>	0.000	0.000	0.055	0.945	Dirichlet

**Table 3. Parameters used in the Decision Model**

<b>Probabilistic Parameters</b>				
<b>Parameter Description</b>	<b>Baseline Estimate</b>	<b>Variation/ SE (SD)</b>	<b>Distribution</b>	<b>Reference</b>
<b>Hospitalisation</b>				
<b>Length of stay in hospital estimate</b>	4.9 days	Alpha 0.1 Beta 316.81	Gamma	<sup>33</sup>
<b>Relative Risk of Hospitalisation with Hawthorn Extract</b>	1.03651200	0.080800494	Lognormal	<sup>36</sup>
<b>Mortality</b>				
<b>Excess Mortality</b>			Beta	<sup>28</sup>
probability of excess mortality given hospitalisation class II	0.01087776	Alpha 0.35916667	Beta 2.55750000	
probability of excess mortality given no hospitalisation class II	0.002620782	Alpha 0.43166667	Beta 13.485000	
probability of excess mortality given hospitalisation class III	0.01791369	Alpha 0.79666667	Beta 3.28666667	
probability of excess mortality given no hospitalisation class III	0.00674466	Alpha 0.72833333	Beta 8.60500000	
probability of excess mortality given hospitalisation class IV	0.05333974	Alpha 0.96416667	Beta 1.03583333	
probability of excess mortality given no hospitalisation class IV	0.00719464	Alpha 0.16583333	Beta 1.83416667	
<b>Relative Risk of Mortality with</b>	0.90336300	0.09507420	Lognormal	<sup>36</sup>



<b>Hawthorn Extract</b>				
<b>Utility</b>			Beta	18
Utility of NYHA class I no hospitalisation	0.815	Alpha 395.88	Beta 89.86	
Utility of NYHA class II no hospitalisation	0.72	Alpha 661.95	Beta 257.42	
Utility of NYHA class III no hospitalisation	0.59	Alpha 359.8075	Beta 250.0357	
Utility of NYHA class IV no hospitalisation	0.508	Alpha 51.77	Beta 50.1394	
<b>Fixed Parameters</b>				
<b>Parameter Description</b>	<b>NYHA class I</b>	<b>NYHA class II</b>	<b>NYHA class III</b>	<b>NYHA class IV</b>
<b>Hospitalisation</b>				32
Probability for hospitalisation	0.01518800	0.02397800	0.02397800	0.15397000
Probability no hospitalisation	0.98481200	0.97602200	0.97602200	0.84603000
<b>Costs</b>				34 35 37
Cost of hospitalisation	\$2,957.08	\$4,435.63	\$4,435.63	\$5,914.17
Total cost for each NYHA class with hospitalisation	\$3,141.60	\$4,639.95	\$4,684.53	\$6,176.17
Cost of each class with no hospitalisation	\$130.30	\$150.11	\$194.69	\$207.79
<b>Mortality</b>				38
<b>Standardised Death Rate</b>	6.0 per 1000	6.0 per 1000	6.0 per 1000	6.0 per 1000

Probabilistic Sensitivity Analysis

Uncertainty is addressed in the model using probabilistic sensitivity analysis. Statistical distributions were assigned to key model parameters to examine second-order uncertainty in the estimation of the parameter. Uncertainty was propagated through the model using Monte Carlo simulation, drawing parameter values at random 1000 times from the particular distributions. This generates a joint density of cost and QALY outcomes that summarises uncertainty in all model parameters.

Net Monetary Benefit

The incremental net monetary benefit was calculated. The difference between the average net benefit of the standard treatment and the average net benefit of the standard treatment with hawthorn as an adjunct is equal to the incremental net benefit.



The net benefit for each treatment is the increase in effectiveness multiplied by the amount the decision maker is willing to pay per QALY (\$40,000), less the increase in cost.

### **The Expected Value of Perfect Information/ Expected Value of Partial Perfect Information (EVPI/ EVPPI)**

The results of the modeling will indicate whether, based on the currently available information, the new treatment should be recommended. This decision is always associated with a level of uncertainty, which raises the question of whether it is appropriate to conduct further research to better examine the potential value of the new treatment, and whether we can identify where this research needs to be directed. EVPI and EVPPI analysis have been used to address these questions.

EVPI analysis is a combination of the cost of making the wrong decision in terms of forgone health benefit and wasted resources, and the probability of making a wrong decision. This equates to the expected cost of uncertainty. With all uncertainty removed there would be economic savings from making the best decision and EVPI is a monetary value of these savings. EVPI provides an upper bound for spending on further research that reduces uncertainty in the decision. EVPPI follows the same principles, but examines individual parameters<sup>39</sup>.

For the model it has been assumed the life of technology is 10 years and the number of eligible patients per annum has been estimated at 30, 000. This estimate is derived from the estimate of 30, 000 new cases of chronic heart failure per annum.

## **RESULTS**

For the standard treatment and standard treatment with hawthorn extract as an adjunct the total cost per patient was \$4,887.82 and \$6754.59 QALYs were 2.40 and 2.42 respectively. This was an incremental cost of \$1866.78 and 0.02 QALYs, and the incremental cost-effectiveness ratio was \$85,160.33 per QALY. A Cost-Effectiveness Plane shows the joint density of cost and QALY outcomes from the Monte Carlo simulations (See Figure 2). In Figure 2, point A is the ICER. The

variation in the model parameters can be seen in a series of histograms for each of the probabilistic parameters (See Appendix 2).

**Cost-Effectiveness Acceptability Curve (CEAC)**

Figure 3 shows the uncertainty around this estimate as a cost-effectiveness acceptability curve (CEAC). At a willingness to pay threshold of \$40,000, the treatment with hawthorn extract has a 0.29 probability of being cost-effective. The probability of being cost effective rises as the willingness to pay threshold rises, for a threshold between \$500,000 and \$1,000,000 the probability is 0.48.

**Net Monetary Benefit (NMB)**

For a threshold of \$40,000, the average incremental NMB is -\$1791.64, the average NMB for the standard treatment is \$92,067.49, and for the standard treatment with hawthorn as an adjunct \$90,275.84. The treatment with hawthorn extract has a negative incremental net benefit, and would not offer good value for money for a decision maker.

**Expected Value of Perfect Information (EVPI)**

The population EVPI has been plotted in Figure 4 for a cost-effectiveness threshold between \$0 and \$200, 000 per QALY. The threshold was continued in the analysis up to a threshold of \$500,000 per QALY, however this did not alter the slope of the curve, so the results up to \$200, 000 have been shown.

If the population EVPI represented in Figure 4 exceeds the expected costs of additional research, then it is potentially cost-effective to conduct further research.

At a threshold of \$40,000 additional research is potentially cost-effective if research is not proposed to cost more than \$325 million.

If we proposed additional research would cost \$100 million, it can be seen from Figure 4 that this research would be potentially cost-effective at a threshold of just under \$16,000. Even at a threshold of \$0 per QALY research would potentially be cost-effective as long as the cost of research did not exceed \$15 million.

The EVPI has indicated further research is potentially cost-effective. The Expected Value of Partial Perfect Information (EVPPPI) was examined to establish where further research would be of most benefit.

### **The Expected Value of Partial Perfect Information (EVPPPI)**

The EVPPPI was examined for six parameters/ groups of parameters, Transitions, Average Length of stay, Excess Mortality (cardiovascular mortality), Relative Risk of Hawthorn, Utilities, and the Relative Risk of Hospitalisation.

The results of the EVPPPI analysis can be seen in Figure 5 (and Table 4). From both the table and figure it can be seen that all parameters and parameter groups have significant EVPPPI, but the impact varies. Utilities (\$439,471,050.98) has the highest EVPPPI, and is therefore the most important target parameter/ parameter group for further research.

**Table 4. Partial EVPI Values for Parameters/ Parameter Groups**

Parameters	Partial EVPI
Transitions	\$7,153,571.92
Average Length of stay	\$96,900,062.41
Excess Mortality	\$105,833,952.26
Relative Risk Hawthorn	\$86,323,972.20
Utilities	\$439,471,050.98
Relative Risk Hospitalisation	\$56,991,399.70

## **DISCUSSION**

In this modelling study we examined the cost-effectiveness of hawthorn extract in addition to standard treatment for heart failure in Australia. This treatment is not considered cost-effective given the current evidence. This is the first known attempt to examine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment of chronic heart failure in Australia. Economic evaluation has been conducted examining hawthorn extract and standard heart failure treatment in Germany and this research indicates hawthorn extract was cost-effective in the

study context, however, these studies were not considered rigorous enough for the data to be used in this study<sup>10 40</sup>.

EVPI analysis indicated that further research was likely to be of benefit, and EVPPI analysis indicated that research ideally should be targeted toward Utilities. The potential costs of further research and the particular type or types that may be required are of crucial importance to the final decision. Further research to examine Utilities will likely rely on primary data from randomized controlled trials such as the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure Study (SENIORS)<sup>18 41</sup>. Alternatively such research would require the initiation of novel research with utilities as a main outcome. This is costly research and this would certainly need to be estimated before any research was undertaken.

The models in any area of health vary in terms of the Markov states chosen, for example when representing the severity of heart failure, hospitalisations and NYHA classes of heart failure are both utilised. It is difficult to summarise the multitude of evidence and compare models as different model structures and methods are used, which potentially leads to different outcomes<sup>42</sup>.

The literature searches conducted for this study were comprehensive, although not to the standard of a systematic review. It is also often seen that the keywords chosen for CAM studies are not always uniform. The combination of these two factors may mean we have missed some of the research available. Our search was not reliant on databases alone, much of our information came from personal correspondence and a thorough search of reference lists, minimizing the impact of the above limitations.

A limitation of this study was the relatively sparse data available for the Australian context. There is scarce data on the incidence and prevalence of heart failure. Estimates rely on information from a small number of large-scale population studies conducted in the United States and Europe<sup>1</sup>. The study of mortality in Australia is complex, heart failure is considered a 'mode of death' not a 'cause of death'. Studies examining mortality in terms of the underlying cause of death risk underestimating

mortality with condition such as heart failure. Mortality statistics are complicated by multiple co-morbidities, which make the underlying cause of death difficult to identify. Lack of consensus about the diagnosis of heart failure also complicates recording of the cause of death, indeed complicating any examination of heart failure. It is difficult to isolate costs for heart failure. Heart failure is grouped by the Australian Institute of Health and Welfare as an 'other cardiovascular disease'. The exact contribution of heart failure to the burden of cardiovascular disease is at best an estimate.

Another limitation was the availability of evidence of the effectiveness of hawthorn extract. There are numerous studies supporting its use, however, very few studies that examine final outcomes such as hospitalisation and mortality<sup>12,30,32</sup>. Previously conducted studies focus on reported outcomes including maximal workload, exercise tolerance, pressure-heart rate product, 6-min walk test, and left-ventricular ejection fraction. There are suggestions in the literature that the use of hawthorn extract can actually decrease the use of standard pharmacological therapy and alter the progression of heart failure, but little rigorous evidence to support this<sup>10</sup>. If the use of standard pharmaceuticals was decreased, and/or disease progression was altered and patients improved their NYHA class to a greater extent or remained in the less symptomatic classes for longer this would decrease costs and potentially change the cost-effectiveness in favour of adding hawthorn extract as an adjunct to standard pharmacological treatment.

Should further evidence become available, the model can easily be updated and the results re-examined.

## CONCLUSION

Our analysis indicates that based on currently available evidence, hawthorn extract is not cost-effective in addition to standard pharmacological treatment for chronic heart failure in Australia. EVPI and EVPPI analysis indicates that further research is warranted, particularly in the area of utilities, pending an assessment of the estimated costs of such research.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests** None.

**Contributors** EF, NG and JA were responsible for the conception and design of the research. EF carried out the data collection and economic analysis. EF was responsible for the original draft. All authors contributed equally to all other aspects including drafting and revising, and approved the final manuscript.

## REFERENCES

1. Krum H, Stewart S. Chronic heart failure: time to recognise this major public health problem. *Med J Aust* 2006;184:147-48.
2. McLean AS, Eslick GD, Coats AJS. The epidemiology of heart failure in Australia. *Int J Cardiol* 2007;118:370-74.
3. Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. *Scand J Prim Health* 2005;23:227-32.
4. Australian Institute of Health and Welfare. Heart failure: what of the future? Cat. No. AUS 34. Canberra: AIHW, 2003.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006., 2006.
6. Krum H, Jelinek MV, Stewart S, et al. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia in 2006. *Med J Aust* 2006;185:549-56.
7. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? *Nat Rev Drug Discov* 2007;6:127-39.
8. Quinn B. Pharmacological treatment of heart failure. *Crit Care Nurs Q* 2007;30:299-306.
9. Furey A, Tassell M. Towards a scientific approach in the assessment of efficacy of an herbal preparation: hawthorn (*Crataegus* spp.). *Eur J Heart Fail* 2008;10:1153-57.



10. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. *Forsch Komp Klas Nat* 2004;11:36-39.
11. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomised trials. *Am J Med* 2003;114:665-74.
12. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure (Review). *Cochrane Database Syst Rev* 2009; Issue 1. Art No: CD005312. DOI: 10.1002/14651858.CD005312.pub2.
13. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. *J Health Serv Res Po* 2008; 13:23-30.
14. Kymes S. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. *Ophthal Epidemiol* 2008;15:76-83.
15. Buxton MJ, Drummond MF, Van Hout BA, *et al.* Modelling in economic evaluation: an unavoidable fact of life. *Health Econ* 1997;6:217-27.
16. Spencer M, Briggs A, Grossman R, *et al.* Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. *Pharmacoeconomics* 2005;23:619-37.
17. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure *Arch Intern Med* 1999;159:1690-700.
18. Yao G, Freemantle N, Flather M, *et al.* Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. *Pharmacoeconomics* 2008;26:879-89.



19. Miller G, Randolph S, Forkner E, *et al.* Long-term cost-effectiveness of disease management in systolic heart failure. *Med Decis Making OnlineFirst* 2009.
20. Yao G, Freemantle N, Calvert M, *et al.* The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J* 2007;28:42-51.
21. Canter P, Thompson-Coon J, Ernst E. Cost effectiveness of complementary treatments in the United Kingdom: a systematic review. *Brit Med J* 2005;331:880-81.
22. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? *Cost Eff Resour Alloc* 2008;6:9.
23. Thompson T, Feder G. Complementary therapies and the NHS: uncertain evidence of cost effectiveness should not exclude complementary medicine from reviews and guidelines. *Brit Med J* 2005;331:856-57.
24. Herman P, Craig B, Caspi O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. *BMC Complem Altern M* 2005;5:11.
25. Hollinghurst S, Sharp D, Ballard K, *et al.* Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. *Brit Med J Online First* 2008;337:a2656.
26. Kim N, Yang B, Lee T, *et al.* An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov model decision analysis. *BMC Complem Altern M* 2010;10:274.

27. Flather M, Shibata M, Coats A, *et al.* Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-25.
28. Muntwyler J, Abetel G, Gruner C, *et al.* One-year mortality among unselected outpatients with heart failure. *Eur Heart J* 2002;23:1861-66.
29. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) - rationale, study design and study protocol. *Eur J Heart Fail* 2000;2:431-37.
30. Zick S, Gillespie B, Aaronson K. The effect of crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10:587-93.
31. Zick S, Vautaw B, Gillespie B, *et al.* Hawthorn extract randomised blinded chronic heart failure (HERB-CHF) trial. *Eur J Heart Fail* 2009;11:990-99.
32. Cowper PA, DeLong ER, Whellan DJ, *et al.* Economic effects of beta-blocker therapy in patients with heart failure. *Am J Med* 2004;116:104-11.
33. Victorian Department of Health. Victorian health services policy and funding guidelines 2010-11 technical guidelines. Melbourne: Victorian Department of Health, 2010.
34. Queensland Health. Casemix funding model 2008-2009: component prices summary. Brisbane: Queensland Government, 2008.
35. Australian Government Department of Health and Ageing. Medicare Benefits Schedule (MBS) online. Canberra: Australian Government Department of Health and Ageing, 2010.

36. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* The efficacy and safety of crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10:1255-63.
37. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. Canberra: Australian Government Department of Health and Ageing, 2010.
38. Australian Bureau of Statistics. 3302.0 - Deaths, Australia, 2008, 2008.
39. Drummond MF, Sculpher MJ, Torrance GW, *et al.* *Methods for the economic evaluation of health care programmes*. Third ed. Oxford: Oxford University Press, 2007.
40. Koller M, Lorenz W, Aubke W, *et al.* Crataegus special extract WS 1442 in the treatment of early stages of CHD-associated heart failure *MMW Fortschr Med* 2006;148:42.
41. Gohler A, Geisler BP, Manne J, *et al.* Utility estimates for decision-analytic modelling in chronic heart failure: health states based on New York heart association classes and number of rehospitalisations. *Value Health* 2009;12:185-87.
42. Turner D, Raftery J, Cooper K, *et al.* The CHD challenge: Comparing four cost-effectiveness models. *Value Health* 2011;14:53-60.

Development of an Economic Model to Assess the Cost-Effectiveness of Hawthorn Extract as an Adjunct Treatment for Heart Failure in Australia

Emily Ford  
School of Population Health  
University of Queensland  
Brisbane, Australia  
Postal address: PO Box 9122  
Wynnum Plaza Queensland 4178  
[emily.ford1@uqconnect.edu.au](mailto:emily.ford1@uqconnect.edu.au)  
Ph +61 (0)7 3901 1429

Professor Jon Adams  
Professor of Public Health  
Faculty of Nursing, Midwifery and Health  
University of Technology  
Sydney, Australia  
and  
Honorary Professor of Sociology  
School of Social Science  
University of Queensland  
Brisbane  
Australia  
[Jon.adams@uts.edu.au](mailto:Jon.adams@uts.edu.au)

Professor Nicholas Graves  
Professor of Health Economics  
School of Public Health and Institute for Health & Biomedical Innovation  
Queensland University of Technology  
Brisbane, Australia  
[n.graves@qut.edu.au](mailto:n.graves@qut.edu.au)

Keywords: complementary therapies, heart failure, cost-benefit analysis, crataegus extract

Word count: 4546

## ABSTRACT

### Objective

An economic model was developed to evaluate the cost-effectiveness of hawthorn extract as an adjunctive treatment for heart failure in Australia.

### Methods

A Markov model of chronic heart failure was developed to compare the costs and outcomes of standard treatment and standard treatment with hawthorn extract. Health states were defined by the New York Heart Association (NYHA) classification system and death. For any given cycle patients could remain in the same NYHA class, experience an improvement or deterioration in NYHA class, be hospitalised or die. Model inputs were derived from the published medical literature, and the output was Quality Adjusted Life Years (QALYs). Probabilistic Sensitivity Analysis was conducted. The Expected Value of Perfect Information (EVPI) and the Expected Value of Partial Perfect Information (EVPPPI) were conducted to establish the value of further research and the ideal target for such research.

### Results

Hawthorn extract increased costs by \$1866.78 and resulted in a gain of 0.02 QALYs. The incremental cost-effectiveness ratio was \$85,160.33 per QALY. The CEAC indicated at a threshold of \$40,000 the new treatment had a 0.29 probability of being cost-effective. The average incremental NMB was -\$1791.64, the average NMB for the standard treatment was \$92,067.49, and for hawthorn extract \$90,275.84. Additional research is potentially cost-effective if research is not proposed to cost more than \$325 million. Utilities is the most important target parameter group for further research.

### Conclusions

Hawthorn extract is not currently considered to be cost-effective in as an adjunctive treatment for heart failure in Australia. Further research in the area of utilities is warranted.

1  
2  
3  
4  
5  
6 **INTRODUCTION**  
7

8  
9 Heart failure is a major public health concern for all Western countries <sup>1</sup>. In the  
10 United States and Europe it is the most common principal diagnosis for adults  
11 admitted to hospital aged 65 years and over. In the United States around 2% of the  
12 population have heart failure (approximately 5 million people), and each year there  
13 are 500, 000 new cases diagnosed <sup>2</sup>. The estimated prevalence in Sweden is 1.5-2%,  
14 approximately 135, 000 to 180, 000 people <sup>3</sup>.  
15  
16

17  
18 Australian data regarding the public health significance and epidemiology of heart  
19 failure is currently limited. Estimates rely on information from large-scale population  
20 studies conducted in the United States and Europe <sup>1</sup>. It is estimated there are  
21 approximately 300,000 Australians living with chronic heart failure, and  
22 approximately 30,000 new cases diagnosed each year, with incidence rates and  
23 prevalence rising significantly with age <sup>4,5</sup>. In Australia, chronic cardiovascular  
24 diseases are associated with health care costs of over five billion dollars, and  
25 estimates put the cost of heart failure at around one billion dollars <sup>6</sup>. The mortality,  
26 morbidity and health care costs of heart failure are therefore significant <sup>4</sup>.  
27  
28

29  
30 Heart failure is a syndrome with a range of signs and symptoms, diagnosis is based on  
31 such signs and symptoms, including dyspnoea and fatigue, and appropriate  
32 investigations, such as echocardiogram, which confirm the presence or absence of  
33 heart failure and help determine its aetiology <sup>1</sup>.  
34  
35

36  
37 Current treatment aims to relieve and stabilise symptoms and prolong survival by  
38 stopping, stabilizing or reversing the progression of heart failure <sup>7</sup>. There are a  
39 variety of strategies used in Australia, including non-pharmacological management,  
40 pharmacological management, lifestyle changes, and the use of supportive devices,  
41 surgery, and palliative care <sup>6,8</sup>. The pharmacological approach depends on the type of  
42 heart failure and extent of the symptoms.  
43  
44

45  
46 Despite the availability of strategies to treat and manage the chronic disease, the  
47 disability and suffering associated with heart failure is devastating <sup>7</sup>. Given this, and  
48 the large economic burden, it is reasonable to examine options not currently  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

considered standard therapy. Research examining the use of complementary and alternative medicine, particularly the use of hawthorn extract is showing promising results.

Hawthorn extract is a popular herbal medicine used worldwide, particularly for its cardiovascular properties<sup>9</sup>. Hawthorn extract has positive inotropic, anti-inflammatory and anti-oxidative properties; causes peripheral and coronary vasodilation; and protects against ischaemia induced arrhythmias<sup>9</sup>. A recent systematic review concluded hawthorn extract can provide significant benefits to heart failure patients as an adjunct to conventional treatment and a recent cost-effectiveness study conducted in Germany concluded hawthorn is a cost-effective treatment option especially in the early stages of heart failure<sup>10-12</sup>.

Economic evaluation is a structured method for examining the costs and consequences involved with alternative methods of treatments and/or programs, in order to inform which is the best alternative from a particular viewpoint<sup>13</sup>. The goal is to improve the use of health care resources and improve patient care<sup>14</sup>. When conducted rigorously, such formal analysis allows recommendation to be made with transparency regarding the methods, data sources and assumptions<sup>13</sup>. This further allows the process to be replicated, reviewed and even challenged.

Models allow complex situations to be organised into a single coherent form that can be used to make decisions based on comprehensive consideration of the alternative interventions by capturing the essential relationships between the factors included in the model and outcomes<sup>15 16</sup>. Markov models define diseases using clinically relevant and economically important health states, between which patients move based on the natural history of the disease, and to which cost and effectiveness outcomes are ascribed<sup>16</sup>.

There are numerous examples of cost-effectiveness modeling in heart failure that examine conventional medicine. Pharmacological, behavioural and surgical interventions have all been investigated and many found to be cost-effective<sup>17 18</sup>. Pharmacological agents that have cost-effectiveness evidence include angiotensin converting enzyme inhibitors (ACEIs), digoxin, and beta-blockers such as carvedilol



and nebivolol. Multidisciplinary heart failure management, in the form of a team, usually made up of a nurse co-ordinator and support from medical staff and allied health including dieticians and physiotherapy, has also shown to be cost-effective through reductions in hospitalisation and length of stay<sup>17 19</sup>. Surgical options including heart transplant, through intensive education and maximal medical therapy, have demonstrated a range of cost-effectiveness values. Cardiac resynchronisation therapy with or without an implantable cardioverter-defibrillator, has shown to be cost-effective from a healthcare perspective<sup>17 20</sup>. Most of the recent evidence involves Markov modeling.

~~The models in any area of health vary in terms of the Markov states chosen, for example when representing the severity of heart failure, hospitalisations and NYHA classes of heart failure are both utilised. It is difficult to summarise the multitude of evidence and compare models as different model structures and methods are used, which potentially leads to different outcomes.~~<sup>21</sup>

Formatted: Highlight

The increasing number of published health economic evaluations is not yet reflected in CAM<sup>21 22 23</sup>. A systematic review examined whether CAM demonstrated cost-effectiveness through economic evaluations<sup>24</sup>. ~~This was based on 56 economic evaluations, 39 full economic evaluations and 14 of appropriate quality for further assessment.~~ There was good evidence for the cost-effectiveness of several therapies in comparison to usual care, acupuncture for migraine, manual therapy for neck pain, spa therapy for Parkinson's, self-administered stress management for cancer patients undergoing chemotherapy, pre- and post-operative oral nutritional supplementation for lower gastrointestinal tract surgery, biofeedback for patients with "functional" disorders (eg, irritable bowel syndrome), and guided imagery, relaxation therapy, and a potassium rich diet for cardiac patients. ~~There were a number of therapies that were cost effective compared to usual care, and evidence to suggest CAM could be cost effective as a complement to usual care.~~<sup>24</sup>

~~It has been several years since this review, but a literature search suggests the situation today is similar. It is possible to identify economic evaluation of CAM, however there remain very few full economic evaluations today. One. An example of such an evaluation, is a study examining therapeutic massage, exercise, and lessons in the Alexander technique for treating persistent back pain<sup>256</sup>. Costs included those to the National Health Service (NHS) and to participants. Outcome~~



measures included the Roland Morris disability score, days in pain, and quality adjusted life years (QALYs). Results included incremental cost effectiveness ratios and cost effectiveness acceptability curves. Massage, lessons in the Alexander technique, and an exercise prescription all provided benefits to patients over a 12-month period. A series of six lessons in the Alexander technique combined with an exercise prescription was the most effective and cost effective option for the NHS<sup>256</sup>.

Some economic evaluations of CAM have incorporated decision modeling. A recent study examined the cost effectiveness of adding acupuncture to usual care for chronic low back pain; was examined from a societal perspective, using a Markov model<sup>267</sup>. The study is led to a gain of 0.13 QALYs at an incremental cost of KRW 459,637, result in an incremental cost per QALY gained of KRW 3,421,394, well below the recommended threshold of based on the per capita gross domestic product in Korea (KRW 20,000,000). Acupuncture plus usual care was more cost effective than usual care for these patients. The probability of collaborative treatment being cost effective was 72.3%. The EVPI analysis suggested further research to reduce the uncertainty around the cost effectiveness of collaborative treatment was of reasonable value. The authors concluded<sup>26</sup>. This highlights the need for full economic evaluations in many areas of CAM.

The aim of this study was the construction and application of an economic decision model to evaluate hawthorn treatment as an adjunct to recommended pharmacological treatment versus recommended pharmacological management for chronic heart failure in Australia. The analysis has been conducted using a health sector perspective.

## METHODS

### Model Description

A four state Markov model of chronic heart failure was developed based on the New York Heart Association (NYHA) classification system using Microsoft Excel® (see Figure 1). Classes I to IV make up four discrete health states included in the model (See Table 1 for a description of the NYHA classes). A decision tree completes the model. Each NYHA class has its own decision tree. Within the decision tree

patients could be hospitalised for worsening heart failure. Patients also either survived or died.

**Progression through the model**

A simulated cohort of 1000 patients aged 60 entered the model with NYHA class II heart failure and progressed through the model. Patients progress through the model in one month cycles for a duration of 5 years. After one month, patients either remained in NYHA class II or improved to NYHA class I or deteriorated. In turn, for each class of heart failure patients were either hospitalised or not hospitalised for worsening heart failure. Patients who were hospitalised or not hospitalised either survived or died. Death was a possibility from any class of heart failure. The patients accrued costs and benefits of treatment in each of the states for each cycle.

Per patient costs were required for each NYHA class. Costs were assumed to be the same for standard treatment and standard treatment with hawthorn extract, except for the additional cost of hawthorn extract. Patient health was considered as a single index utility on a zero to one scale, where 0 represents death and 1 represents perfect health. This allows the calculation of Quality Adjusted Life Years (QALYs) when combined with the mortality data and the calculation of cost per QALY ratios.

Two cohorts were modeled, one receiving standard pharmacological treatment and the other receiving standard pharmacological treatment with hawthorn extract as an adjunct. The two cohorts will progress through the model in slightly different ways and as such there will be a difference in the accumulation of costs and QALYS. It is the differences in costs and QALYs that will determine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment.

A discount rate of 3% per year was applied to the costs and benefits. This rate is a standard choice in the literature.

**Table 1. NYHA grading of symptoms in chronic heart failure.**

NYHA	Description
------	-------------

Class	
Class I	No symptoms and limitations in ordinary physical activity.
Class II	Slight limitation of physical activity. Ordinary physical activity results in mild symptoms such as fatigue, shortness of breath, and angina.
Class III	Marked limitation of physical activity. Less than ordinary physical activity leads to symptoms.
Class IV	Severely limited. Experiences symptoms even at rest.

## Model Construction

### Disease Progression

Transition probabilities for movement between NYHA classes of heart failure were estimated from the published literature detailing the large scale international Study of the Effects of Nebivolol Intervention on Outcomes and Re-hospitalisation in Seniors with Heart Failure (SENIORS) and personal correspondence with authors<sup>18,27</sup>. A thorough literature search was conducted to identify disease progression data for each NYHA class, between January 2004 and December 2009. Data was considered relevant if transition probabilities were provided for each NYHA class. The databases searched were Medline, CINAHL and the Cochrane Library. Search terms used included 'New York Heart Association', 'NYHA', 'NYHA class', 'class', 'Markov model', 'chronic heart failure', and 'heart failure'.

The search yielded a limited number of studies (17 in Medline, 3 in CINAHL and 3 in the Cochrane library), of which only the above study was considered suitable for inclusion.

Disease progression between the Markov states was assumed to be the same for standard treatment and for standard treatment with hawthorn extract, as we were unable to identify reliable data to indicate that hawthorn extract altered progression through the classes of heart failure. Transition probabilities were fixed over time. We have incorporated a difference in mortality and a difference in the hospitalisation rate between the standard treatment and the standard treatment with hawthorn extract as an adjunct, which in turn will impact on the cost and QALY outcomes.

## Data Sources

### Mortality

Baseline mortality was derived from Australian Bureau of Statistics general population mortality data.

Mortality data was of interest if it was provided for each NYHA class and if it concerned the excess mortality from heart failure and/or cardiovascular causes. The databases searched were Medline, CINAHL and the Cochrane Library, between January 2004 and December 2009. Search terms used included ‘New York Heart Association’, ‘NYHA’, ‘NYHA class’, ‘class’, ‘Markov model’, ‘chronic heart failure’, ‘heart failure’, ‘mortality’. 83 papers were identified in Medline, 198 in CINAHL and 411 in Cochrane.

The mortality rate for cardiovascular causes was derived from the published literature detailing one-year mortality among unselected patients with NYHA class II-IV heart failure in Switzerland<sup>28</sup>. The mortality rate increased with progression from NYHA class I to NYHA class IV, and varied depending on whether the patient was hospitalised or not. A thorough search of the literature was made to identify data for each NYHA class individually, nothing was identified and the above study was the closest to ideal. Hospitalisation was considered a major factor in cost estimation, so data broken down by hospitalisation status was considered to represent the population of heart failure patients well. Also, unselected patients were considered to represent the patient cohort more accurately than studies that focused on hospitalised patients only. As data for NYHA class I was not included, an assumption was made that mortality for NYHA class I was the same as the general population mortality.

Health Status

Estimates of health status were derived from the same source as the transition probabilities<sup>18 20</sup>. Data concerning utilities for heart failure is extremely limited, a study was identified that had specifically had developed utilities for heart failure in terms of both hospitalisation and NYHA class. However, we were unable to obtain the required data despite personal correspondence with the authors. The estimated health status used was considered the next best data source.

Health status was assumed to be the same for standard treatment and standard treatment with hawthorn extract. Hospitalisation was assumed to result in a health state lower than non-hospitalisation and a -0.1 disutility was applied to hospitalisation to reflect this.

## Effect of Hawthorn

A literature search identified the existing research for the use of hawthorn extract in the treatment of heart failure between January 2004 and January 2010. The search included electronic databases (Medline, ~~PubMed~~, ~~CAM on PubMed~~, (472 papers) AMED (129 papers), Econlit (0 papers), ~~DynaMed~~, CINAHL (15 papers), Cochrane Database of Systematic Reviews (71 papers)), hand searches of the literature, including hard copies of journals, and a search of the reference lists of the articles and publications found through electronic and hand searches. Personal communication with authors and experts including manufacturers and researchers in the field was also necessary to identify other sources of information and research that may not have been found using any other methods.

A wide range of search terms was used including: 'heart failure', 'chronic heart failure', 'systolic heart failure', and 'congestive heart failure', 'hawthorn', 'Crataegus', 'Crataegus oxyacantha', 'Crataegus monogyna', 'whitethorn', 'weissdorn', 'Crataegus laevigata', 'WS 1442', 'LI 132', 'complementary', 'alternative', 'medicine' and 'therapy'. There were several studies written in German, these were translated into English and then examined.

Publicly accessible trials registers were also searched, and information was current up to December 2011. The Australian New Zealand Clinical Trials Registry (ANZCTR) was searched, no studies were identified. The World Health Organisation International Clinical Trials Registry Platform was searched, no new relevant trials were identified. The search terms used were: 'hawthorn extract', 'hawthorn', 'crataegus', 'WS1442', 'whitehorn', 'heart failure'.

There were no planned exclusion criteria at this stage for the patient population as any of the studies found have the potential to contribute valuable information to inform the model development.

The relative risk of mortality and relative risk of hospitalisation with hawthorn extract was derived from the Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE) trial, a large scale, international, randomised, placebo-controlled, double-blind study designed to investigate the influence of

hawthorn extract on mortality of patients with congestive heart failure NYHA class II and III with at least moderately impaired left ventricular function<sup>29</sup>. To date there have only been two studies to examine the effect of hawthorn extract on heart failure progression in terms of mortality and hospitalisation. Most studies have focused on symptoms and exercise capability. SPICE enrolled 2681 patients, and the Hawthorn Extract Randomised Blinded Chronic Heart Failure (HERB CHF) trial enrolled 120 patients<sup>30 31</sup>. Meta-analysis was not considered appropriate, therefore the data from SPICE was incorporated into the model.

Costs

No Australian data was available to estimate the hospitalisation rate and number of hospitalisations, this information was derived from a United States study<sup>32</sup>. The estimated length of stay in hospital data was obtained from Victorian Department of Health for 2010-2011, it was unavailable for each NYHA class, so it was assumed to be the same for all classes<sup>33</sup>.

The cost of a hospital admission per day was derived from the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary (\$3,775 per day)<sup>34</sup>. Outpatient costs included General Practitioner (GP) visits, pathology (urea, creatinine, electrolytes), echocardiograms, and specialist visits. Estimates of the number of GP and specialist visits came from a combination of Australian sources and overseas studies due to the difficulty in finding complete Australian estimates. It was estimated that NYHA class I had 6 GP visits per year, and the remaining NYHA classes had 12 visits per year at \$34.30 per visit. Pathology was assumed to be required every 3 months at a cost of \$17.80. An Echocardiogram was assumed to be performed every two years (\$230.65). A specialist visit was assumed to occur twice per year (\$290 initial visit, \$194 repeat visit). If hospitalized, it was assumed patients had an extra 3 specialist visits and 2 GP visits per year. The costs came directly from the Medicare Benefits Schedule and the Queensland Government/ Queensland Health Casemix Funding Model 2008-2009 Component Prices Summary<sup>34 35</sup>.

The information for which medications are taken for each NYHA class have been taken from the National Heart Foundation guidelines for the treatment of chronic heart failure in Australia<sup>5</sup>. Information for the optimal dosages prescribed has been taken from the Australian Therapeutic Guidelines. Individual drug pricing was

obtained from the most recently available online version of the Medicare Benefits Schedule. The initial version of the model has incorporated the assumption that medications are taken in 100% of patients and that dosing is optimal. The model however can be altered to consider different scenarios of medication prescription and consumption.

The dosage was assumed to be 900mg daily, consistent with the dosage used in the two most recent trials of hawthorn extract, the SPICE trial and the HERB-CHF trial<sup>29 31 36</sup>. An online search was conducted for standardised monopreparations of hawthorn leaf with flower available for purchase. Cardiomax® retails for A\$25.95 for 30 x 450mg tablets (this equates to a 15 day supply, the cost for one month is \$51.90).

The transition parameters are listed in Table 2. The model parameters have been listed in Table 3. Appendix 1 details the calculation of transition probabilities for the model.

**Table 2. Transition Parameters used in the Decision Model**

<i>Transition Matrix</i>	NYHA I	NYHA II	NYHA III	NYHA IV	Distribution
NYHA I	0.977	0.019	0.004	0.000	Dirichlet
NYHA II	0.008	0.981	0.010	0.001	Dirichlet
NYHA III	0.000	0.034	0.960	0.006	Dirichlet
NYHA IV	0.000	0.000	0.055	0.945	Dirichlet

**Table 3. Parameters used in the Decision Model**

Probabilistic Parameters				
Parameter Description	Baseline Estimate	Variation/ SE (SD)	Distribution	Reference
<b>Hospitalisation</b>				
Length of stay in hospital estimate	4.9 days	Alpha 0.1 Beta 316.81	Gamma	<sup>33</sup>
Relative Risk of Hospitalisation with Hawthorn Extract	1.03651200	0.080800494	Lognormal	<sup>36</sup>
<b>Mortality</b>				
Excess Mortality			Beta	<sup>28</sup>



probability of excess mortality given hospitalisation class II	0.01087776	Alpha 0.35916667	Beta 2.55750000	
probability of excess mortality given no hospitalisation class II	0.002620782	Alpha 0.43166667	Beta 13.485000	
probability of excess mortality given hospitalisation class III	0.01791369	Alpha 0.79666667	Beta 3.28666667	
probability of excess mortality given no hospitalisation class III	0.00674466	Alpha 0.72833333	Beta 8.60500000	
probability of excess mortality given hospitalisation class IV	0.05333974	Alpha 0.96416667	Beta 1.03583333	
probability of excess mortality given no hospitalisation class IV	0.00719464	Alpha 0.16583333	Beta 1.83416667	
<b>Relative Risk of Mortality with Hawthorn Extract</b>	0.90336300	0.09507420	Lognormal	<sup>36</sup>
<b>Utility</b>			Beta	<sup>18</sup>
Utility of NYHA class I no hospitalisation	0.815	Alpha 395.88	Beta 89.86	
Utility of NYHA class II no hospitalisation	0.72	Alpha 661.95	Beta 257.42	
Utility of NYHA class III no hospitalisation	0.59	Alpha 359.8075	Beta 250.0357	
Utility of NYHA class IV no hospitalisation	0.508	Alpha 51.77	Beta 50.1394	
<b>Fixed Parameters</b>				
<b>Parameter Description</b>	<b>NYHA class I</b>	<b>NYHA class II</b>	<b>NYHA class III</b>	<b>NYHA class IV</b>
<b>Hospitalisation</b>				<sup>32</sup>
Probability for hospitalisation	0.01518800	0.02397800	0.02397800	0.15397000
Probability no hospitalisation	0.98481200	0.97602200	0.97602200	0.84603000
<b>Costs</b>				<sup>34 35 37</sup>
Cost of hospitalisation	\$2,957.08	\$4,435.63	\$4,435.63	\$5,914.17



Total cost for each NYHA class with hospitalisation	\$3,141.60	\$4,639.95	\$4,684.53	\$6,176.17
Cost of each class with no hospitalisation	\$130.30	\$150.11	\$194.69	\$207.79
<b>Mortality</b>				<sup>38</sup>
<b>Standardised Death Rate</b>	6.0 per 1000	6.0 per 1000	6.0 per 1000	6.0 per 1000

### Probabilistic Sensitivity Analysis

Uncertainty is addressed in the model using probabilistic sensitivity analysis. Statistical distributions were assigned to key model parameters to examine second-order uncertainty in the estimation of the parameter. Uncertainty was propagated through the model using Monte Carlo simulation, drawing parameter values at random 1000 times from the particular distributions. This generates a joint density of cost and QALY outcomes that summarises uncertainty in all model parameters.

### Net Monetary Benefit

The incremental net monetary benefit was calculated. The difference between the average net benefit of the standard treatment and the average net benefit of the standard treatment with hawthorn as an adjunct is equal to the incremental net benefit. The net benefit for each treatment is the increase in effectiveness multiplied by the amount the decision maker is willing to pay per QALY (\$40,000), less the increase in cost.

### The Expected Value of Perfect Information/ Expected Value of Partial Perfect Information (EVPI/ EVPPI)

The results of the modeling will indicate whether, based on the currently available information, the new treatment should be recommended. This decision is always associated with a level of uncertainty, which raises the question of whether it is appropriate to conduct further research to better examine the potential value of the new treatment, and whether we can identify where this research needs to be directed. EVPI and EVPPI analysis have been used to address these questions.

EVPI analysis is a combination of the cost of making the wrong decision in terms of forgone health benefit and wasted resources, and the probability of making a wrong

1  
2  
3  
4  
5  
6 decision. This equates to the expected cost of uncertainty. With all uncertainty  
7 removed there would be economic savings from making the best decision and EVPI is  
8 a monetary value of these savings. EVPI provides an upper bound for spending on  
9 further research that reduces uncertainty in the decision. EVPPI follows the same  
10 principles, but examines individual parameters <sup>39</sup>.

11  
12  
13  
14  
15 For the model it has been assumed the life of technology is 10 years and the number  
16 of eligible patients per annum has been estimated at 30, 000. This estimate is derived  
17 from the estimate of 30, 000 new cases of chronic heart failure per annum.

18  
19  
20  
21 **RESULTS**

22  
23 For the standard treatment and standard treatment with hawthorn extract as an adjunct  
24 the total cost per patient was \$4,887.82 and \$6754.59 QALYs were 2.40 and 2.42  
25 respectively. This was an incremental cost of \$1866.78 and 0.02 QALYs, and the  
26 incremental cost-effectiveness ratio was \$85,160.33 per QALY. A Cost-  
27 Effectiveness Plane shows the joint density of cost and QALY outcomes from the  
28 Monte Carlo simulations (See [Figure Appendix 2](#)). [In Figure 2, point A is the ICER.](#)  
29 The variation in the model parameters can be seen in a series of histograms for each  
30 of the probabilistic parameters (See Appendix [23](#)).

31  
32  
33  
34  
35  
36 **Cost-Effectiveness Acceptability Curve (CEAC)**

37  
38 Figure [32](#) shows the uncertainty around this estimate as a cost-effectiveness  
39 acceptability curve (CEAC). At a willingness to pay threshold of \$40,000, the  
40 treatment with hawthorn extract has a 0.29 probability of being cost-effective. The  
41 probability of being cost effective rises as the willingness to pay threshold rises, for a  
42 threshold between \$500,000 and \$1,000,000 the probability is 0.48.

43  
44  
45  
46 **Net Monetary Benefit (NMB)**

47  
48 For a threshold of \$40,000, the average incremental NMB is -\$1791.64, the average  
49 NMB for the standard treatment is \$92,067.49, and for the standard treatment with  
50 hawthorn as an adjunct \$90,275.84. The treatment with hawthorn extract has a  
51 negative incremental net benefit, and would not offer good value for money for a  
52 decision maker.

### Expected Value of Perfect Information (EVPI)

The population EVPI has been plotted in Figure 43 for a cost-effectiveness threshold between \$0 and \$200, 000 per QALY. The threshold was continued in the analysis up to a threshold of \$500,000 per QALY, however this did not alter the slope of the curve, so the results up to \$200, 000 have been shown.

If the population EVPI represented in Figure 43 exceeds the expected costs of additional research, then it is potentially cost-effective to conduct further research.

At a threshold of \$40,000 additional research is potentially cost-effective if research is not proposed to cost more than \$325 million.

If we proposed additional research would cost \$100 million, it can be seen from Figure 43 that this research would be potentially cost-effective at a threshold of just under \$16,000. Even at a threshold of \$0 per QALY research would potentially be cost-effective as long as the cost of research did not exceed \$15 million.

The EVPI has indicated further research is potentially cost-effective. The Expected Value of Partial Perfect Information (EVPPI) was examined to establish where further research would be of most benefit.

### The Expected Value of Partial Perfect Information (EVPPI)

The EVPPI was examined for six parameters/ groups of parameters, Transitions, Average Length of stay, Excess Mortality (cardiovascular mortality), Relative Risk of Hawthorn, Utilities, and the Relative Risk of Hospitalisation.

The results of the EVPPI analysis can be seen in Figure 54 (and Table 4). From both the table and figure it can be seen that all parameters and parameter groups have significant EVPPI, but the impact varies. Utilities (\$439,471,050.98) has the highest EVPPI, and is therefore the most important target parameter/ parameter group for further research.

**Table 4. Partial EVPI Values for Parameters/ Parameter Groups**

Parameters	Partial EVPI
Transitions	\$7,153,571.92
Average Length of stay	\$96,900,062.41
Excess Mortality	\$105,833,952.26
Relative Risk Hawthorn	\$86,323,972.20
Utilities	\$439,471,050.98
Relative Risk Hospitalisation	\$56,991,399.70

DISCUSSION

In this modelling study we examined the cost-effectiveness of hawthorn extract in addition to standard treatment for heart failure in Australia. This treatment is not considered cost-effective given the current evidence. This is the first known attempt to examine the cost-effectiveness of hawthorn extract in addition to standard pharmacological treatment of chronic heart failure in Australia. Economic evaluation has been conducted examining hawthorn extract and standard heart failure treatment in Germany and this research indicates hawthorn extract was cost-effective in the study context, however, these studies were not considered rigorous enough for the data to be used in this study<sup>10 40</sup>.

EVPI analysis indicated that further research was likely to be of benefit, and EVPPI analysis indicated that research ideally should be targeted toward Utilities. The potential costs of further research and the particular type or types that may be required are of crucial importance to the final decision. Further research to examine Utilities will likely rely on primary data from randomized controlled trials such as the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure Study (SENIORS)<sup>18 41</sup>. Alternatively such research would require the initiation of novel research with utilities as a main outcome. This is costly research and this would certainly need to be estimated before any research was undertaken.

The models in any area of health vary in terms of the Markov states chosen, for example when representing the severity of heart failure, hospitalisations and NYHA classes of heart failure are both utilised. It is difficult to summarise the multitude of evidence and compare models as different model structures and methods are used, which potentially leads to different outcomes<sup>42</sup>.

The literature searches conducted for this study were comprehensive, although not to the standard of a systematic review. It is also often seen that the keywords chosen for CAM studies are not always uniform. The combination of these two factors may mean we have missed some of the research available. Our search was not reliant on databases alone, much of our information came from personal correspondence and a thorough search of reference lists, minimizing the impact of the above limitations.

A limitation of this study was the relatively sparse data available for the Australian context. There is scarce data on the incidence and prevalence of heart failure. Estimates rely on information from a small number of large-scale population studies conducted in the United States and Europe<sup>1</sup>. The study of mortality in Australia is complex, heart failure is considered a 'mode of death' not a 'cause of death'. Studies examining mortality in terms of the underlying cause of death risk underestimating mortality with condition such as heart failure. Mortality statistics are complicated by multiple co-morbidities, which make the underlying cause of death difficult to identify. Lack of consensus about the diagnosis of heart failure also complicates recording of the cause of death, indeed complicating any examination of heart failure. It is difficult to isolate costs for heart failure. Heart failure is grouped by the Australian Institute of Health and Welfare as an 'other cardiovascular disease'. The exact contribution of heart failure to the burden of cardiovascular disease is at best an estimate.

Another limitation was the availability of evidence of the effectiveness of hawthorn extract. There are numerous studies supporting its use, however, very few studies that examine final outcomes such as hospitalisation and mortality<sup>12,30,32</sup>. Previously conducted studies focus on reported outcomes including maximal workload, exercise tolerance, pressure-heart rate product, 6-min walk test, and left-ventricular ejection fraction. There are suggestions in the literature that the use of hawthorn extract can

actually decrease the use of standard pharmacological therapy and alter the progression of heart failure, but little rigorous evidence to support this <sup>10</sup>. If the use of standard pharmaceuticals was decreased, and/or disease progression was altered and patients improved their NYHA class to a greater extent or remained in the less symptomatic classes for longer this would decrease costs and potentially change the cost-effectiveness in favour of adding hawthorn extract as an adjunct to standard pharmacological treatment.

Should further evidence become available, the model can easily be updated and the results re-examined.

**CONCLUSION**

Our analysis indicates that based on currently available evidence, hawthorn extract is not cost-effective in addition to standard pharmacological treatment for chronic heart failure in Australia. EVPI and EVPPI analysis indicates that further research is warranted, particularly in the area of utilities, pending an assessment of the estimated costs of such research.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing Interests** None.

**Contributors** EF, NG and JA were responsible for the conception and design of the research. EF carried out the data collection and economic analysis. EF was responsible for the original draft. All authors contributed equally to all other aspects including drafting and revising, and approved the final manuscript.

## REFERENCES

1. Krum H, Stewart S. Chronic heart failure: time to recognise this major public health problem. *Med J Aust* 2006;184:147-48.
2. McLean AS, Eslick GD, Coats AJS. The epidemiology of heart failure in Australia. *Int J Cardiol* 2007;118:370-74.
3. Agvall B, Borgquist L, Foldevi M, Dahlstrom U. Cost of heart failure in Swedish primary healthcare. *Scand J Prim Health* 2005;23:227-32.
4. Australian Institute of Health and Welfare. Heart failure: what of the future? Cat. No. AUS 34. Canberra: AIHW, 2003.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006., 2006.
6. Krum H, Jelinek MV, Stewart S, *et al.* Guidelines for the prevention, detection and management of people with chronic heart failure in Australia in 2006. *Med J Aust* 2006;185:549-56.
7. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? *Nat Rev Drug Discov* 2007;6:127-39.
8. Quinn B. Pharmacological treatment of heart failure. *Crit Care Nurs Q* 2007;30:299-306.
9. Furey A, Tassell M. Towards a scientific approach in the assessment of efficacy of an herbal preparation: hawthorn (*Crataegus* spp.). *Eur J Heart Fail* 2008;10:1153-57.

10. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. *Forsch Komp Klas Nat* 2004;11:36-39.

11. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomised trials. *Am J Med* 2003;114:665-74.

12. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure (Review). *Cochrane Database Syst Rev* 2009; Issue 1. Art No: CD005312. DOI: 10.1002/14651858.CD005312.pub2.

13. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. *J Health Serv Res Po* 2008; 13:23-30.

14. Kymes S. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. *Ophthal Epidemiol* 2008;15:76-83.

15. Buxton MJ, Drummond MF, Van Hout BA, *et al.* Modelling in economic evaluation: an unavoidable fact of life. *Health Econ* 1997;6:217-27.

16. Spencer M, Briggs A, Grossman R, *et al.* Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. *Pharmacoeconomics* 2005;23:619-37.

17. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure *Arch Intern Med* 1999;159:1690-700.

18. Yao G, Freemantle N, Flather M, *et al.* Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. *Pharmacoeconomics* 2008;26:879-89.



19. Miller G, Randolph S, Forkner E, *et al.* Long-term cost-effectiveness of disease management in systolic heart failure. *Med Decis Making OnlineFirst* 2009.
20. Yao G, Freemantle N, Calvert M, *et al.* The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J* 2007;28:42-51.
21. Canter P, Thompson-Coon J, Ernst E. Cost effectiveness of complementary treatments in the United Kingdom: a systematic review. *Brit Med J* 2005;331:880-81.
22. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? *Cost Eff Resour Alloc* 2008;6:9.
23. Thompson T, Feder G. Complementary therapies and the NHS: uncertain evidence of cost effectiveness should not exclude complementary medicine from reviews and guidelines. *Brit Med J* 2005;331:856-57.
24. Herman P, Craig B, Caspi O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. *BMC Complem Altern M* 2005;5:11.
25. Hollinghurst S, Sharp D, Ballard K, *et al.* Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain: economic evaluation. *Brit Med J Online First* 2008;337:a2656.
26. Kim N, Yang B, Lee T, *et al.* An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov model decision analysis. *BMC Complem Altern M* 2010;10:274.

27. Flather M, Shibata M, Coats A, *et al*. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-25.

28. Muntwyler J, Abetel G, Gruner C, *et al*. One-year mortality among unselected outpatients with heart failure. *Eur Heart J* 2002;23:1861-66.

29. Holubarsch CJF, Colucci WS, Meinertz T, *et al*. Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) - rationale, study design and study protocol. *Eur J Heart Fail* 2000;2:431-37.

30. Zick S, Gillespie B, Aaronson K. The effect of crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10:587-93.

31. Zick S, Vautaw B, Gillespie B, *et al*. Hawthorn extract randomised blinded chronic heart failure (HERB-CHF) trial. *Eur J Heart Fail* 2009;11:990-99.

32. Cowper PA, DeLong ER, Whellan DJ, *et al*. Economic effects of beta-blocker therapy in patients with heart failure. *Am J Med* 2004;116:104-11.

33. Victorian Department of Health. Victorian health services policy and funding guidelines 2010-11 technical guidelines. Melbourne: Victorian Department of Health, 2010.

34. Queensland Health. Casemix funding model 2008-2009: component prices summary. Brisbane: Queensland Government, 2008.

35. Australian Government Department of Health and Ageing. Medicare Benefits Schedule (MBS) online. Canberra: Australian Government Department of Health and Ageing, 2010.

36. Holubarsch CJF, Colucci WS, Meinertz T, *et al.* The efficacy and safety of crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10:1255-63.
37. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. Canberra: Australian Government Department of Health and Ageing, 2010.
38. Australian Bureau of Statistics. 3302.0 - Deaths, Australia, 2008, 2008.
39. Drummond MF, Sculpher MJ, Torrance GW, *et al.* *Methods for the economic evaluation of health care programmes*. Third ed. Oxford: Oxford University Press, 2007.
40. Koller M, Lorenz W, Aubke W, *et al.* Crataegus special extract WS 1442 in the treatment of early stages of CHD-associated heart failure *MMW Fortschr Med* 2006;148:42.
41. Gohler A, Geisler BP, Manne J, *et al.* Utility estimates for decision-analytic modelling in chronic heart failure: health states based on New York heart association classes and number of rehospitalisations. *Value Health* 2009;12:185-87.
42. Turner D, Raftery J, Cooper K, *et al.* The CHD challenge: Comparing four cost-effectiveness models. *Value Health* 2011;14:53-60.






Figure 1. Markov model and decision tree showing transitions between potential health states for chronic heart failure.


451x317mm (300 x 300 DPI)




Cost Effectiveness Plane  
150x84mm (300 x 300 DPI)



Cost Effectiveness Acceptability Curve (CEAC)  
162x90mm (300 x 300 DPI)



Expected Value of Perfect Information (EVPI)  
161x91mm (300 x 300 DPI)



Expected Value of Partial Perfect Information (EVPPPI)  
149x91mm (300 x 300 DPI)



## Appendix 1. Calculation of the Transition Probabilities for the Markov Model

transition matrix	NYHA I	NYHA II	NYHA III	NYHA IV	Check
NYHA I	0.977	0.019	0.004	0.000	1.000
NYHA II	0.008	0.981	0.010	0.001	1.000
NYHA III	0.000	0.034	0.960	0.006	1.000
NYHA IV	0.000	0.000	0.055	0.945	1.000
					0.000

Probabilistic version

### 1. Observed counts

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	59.597	1.159	0.244	0	61
NYHA II	9.6	1177.2	12	1.2	1200
NYHA III	0	28.016	791.04	4.944	824
NYHA IV	0	0	2.365	40.635	43
					2128

### 2. Estimated probabilities

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	0.977	0.019	0.004	0	1
NYHA II	0.008	0.981	0.010	0.001	1
NYHA III	0	0.034	0.960	0.006	1
NYHA IV	0	0	0.055	0.945	1

### 3. Random number table

	NYHA I	NYHA II	NYHA III	NYHA IV
NYHA I	0.24	0.44	0.87	0.66
NYHA II	0.91	0.62	0.99	0.21
NYHA III	0.72	0.91	0.27	0.46
NYHA IV	0.26	0.18	0.92	0.46


### 4. Cumulative gamma/normal functions


	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	53.905	0.730	0.568	0	55
NYHA II	13.845	1188.106	20.983	0.342	1223
NYHA III	0	35.377	773.741	4.390	814
NYHA IV	0	0	4.735	39.593	44


### 5. Random dirichlet probabilities

	NYHA I	NYHA II	NYHA III	NYHA IV	totals
NYHA I	0.976	0.013	0.010	0	1.00
NYHA II	0.011	0.971	0.017	0.000	1.00
NYHA III	0	0.043	0.951	0.005	1.00
NYHA IV	0	0	0.107	0.893	1.00

Appendix 3. Histograms of Individual Parameters







## EVEREST Statement: Checklist for health economics paper

	Study section	Additional remarks
<b>Study design</b>		
(1) The research question is stated	Introduction	
(2) The economic importance of the research question is stated	Introduction	
(3) The viewpoint(s) of the analysis are clearly stated and justified	Introduction	
(4) The rationale for choosing the alternative programmes or interventions compared is stated	Introduction	
(5) The alternatives being compared are clearly described	Introduction; Methods	
(6) The form of economic evaluation used is stated	Introduction; Methods	
(7) The choice of form of economic evaluation is justified in relation to the questions addressed	Methods; Discussion	
<b>Data collection</b>		
(8) The source(s) of effectiveness estimates used are stated	Methods	Presented in table form and in written form
(9) Details of the design and results of effectiveness study are given (if based on single study)	N/A	Data derived from multiple sources
(10) Details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a number of effectiveness studies)	N/A	Meta-analysis was not used
(11) The primary outcome measure(s) for the economic evaluation are clearly stated	Methods	
(12) Methods to value health states and other benefits are stated	Methods	
(13) Details of the subjects from whom valuations were obtained are given	N/A	
(14) Productivity changes (if included) are reported separately	N/A	
(15) The relevance of productivity changes to the study question is discussed	N/A	
(16) Quantities of resources are reported separately from their unit costs	Methods	
(17) Methods for the estimation of quantities and unit costs are described	Methods	
(18) Currency and price data are recorded	Methods	
(19) Details of currency of price adjustments for	NA	As the study is

inflation or currency conversion are given		looking for relative cost, then inflation would be comparable between the different treatments
(20) Details of any model used are given	Methods	
(21) The choice of model used and the key parameters on which it is based are justified	Methods	
<b>Analysis and interpretation of results</b>		
(22) Time horizon of costs and benefits is stated	Methods-Model construction; Discussion	Based on current cost estimates
(23) The discount rate(s) is stated	Methods	
(24) The choice of rate(s) is justified	N/A	
(25) An explanation is given if costs or benefits are not discounted	N/A	
(26) Details of statistical tests and confidence intervals are given for stochastic data	N/A	
(27) The approach to sensitivity analysis is given	Methods	
(28) The choice of variables for sensitivity analysis is justified	Methods	
(29) The ranges over which the variables are varied are stated	Methods, Table 2	
(30) Relevant alternatives are compared	Methods	
(31) Incremental analysis is reported	Results	
(32) Major outcomes are presented in a disaggregated as well as aggregated form	Results	
(33) The answer to the study question is given	Results Discussion; Conclusion	
(34) Conclusions follow from the data reported	Discussion; Conclusion	
(35) Conclusions are accompanied by the appropriate caveats	Discussion; Conclusion	